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ABSTRACT

Role of Zmpste24 in Prelamin A Maturation
by
Douglas P. Corrigan

The nuclear lamins form a karyoskeleton providing structural rigidity to the nucleus. One
member of the lamin family, lamin A, is first synthesized as a 74 kDa precursor, prelamin
A. Following the endopeptidase and methylation reactions which occur after farnesylation
of the CAAX-box cysteine, there is a second endoproteolysis that occurs 15 amino acids
upstream from the C-terminal farnesylated cysteine residue. Studies with knockout mice
have implicated the enzyme Zmpste24 as a candidate to carry out one or both of these
proteolytic reactions. In this body of work, the CAAX endopeptidase activity of
recombinant, membrane reconstituted, Zmpste24 is demonstrated using a prelamin A
farnesylated tetrapeptide as substrate. To monitor the second upstream endoproteolytic
cleavage a 33 kDa prelamin A carboxyl terminal tail of prelamin A was expressed in insect
cells. This purified substrate possesses a fully processed CAAX box, and, therefore,
constitutes a valid substrate for assaying the second endoproteolytic step in lamin A
maturation. In vitro reactions with this substrate and insect cell membranes bearing
recombinant Zmpste24 demonstrate that Zmpste24 may possess the ability to directly
catalyze the second endoproteolytic cleavage. Previous studies on nuclear envelope
fractions have ascribed this second activity to a chymotrypsin like protease. However,
Zmpste24 contains the canonical HEXXH domain, a common characteristic of zinc
2

metalloproteinases. Experiments on Zmpste24 in this work demonstrate that inactivating
the HEXXH domain by site directed mutagenesis results in a loss of the first
endoproteolysis reaction, while the second endoproteolytic activity is retained. Supporting
these data is the observation that a truncated mutant of Zmpste24 (residues: Met1 - Pro230)
that does not contain the HEXXH motif, loses the first endoproteolytic activity while
retaining the second. Furthermore, this second activity is not sensitive to the
metalloproteinase inhibitors EDTA and 1,10-orthophenanthroline but is sensitive to the
chymotrypsin inhibitor TPCK and its fluorescent analogue, FFCK. The fact that Zmpste24
can be affinity labeled with FFCK suggests that this second activity is directly caused by a
second, yet unidentified, active site with a chymotrypsin-like catalytic mechanism.
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CHAPTER 1
INTRODUCTION

The Nuclear Envelope
At the center of the eukaryotic cell is the complex and dynamic structure of the
nucleus, a multifunctional organelle that: 1) stores genetic information in the form of
chromatin; 2) regulates gene expression, and 3) controls the overall dynamics of the
mitotic process (Lamond and Earnshaw 1998; Mizuno 1999). Separation of the contents
of the nucleus from the rest of the cell is governed by the structure of the nuclear
envelope, a dual membranous structure containing both phospholipids and proteins
(Dessev 1992). Not only does the nuclear envelope provide a static structural role for
defining the boundaries of the nucleus, it also plays a dynamic role in gene regulation by
providing attachment points for chromatin and other genetic regulatory factors that
influence the transcription of genes (Pfaller and Newport 1995; Marshall and others
1996). In addition to these roles, the nuclear envelope contains channels known as
nuclear pores that govern the regulated passage of mRNA and other signaling molecules
that transmit information from the cytosol to the nucleus (Macara 2001). Complex
signaling pathways that originate at the periphery of the cell via protein receptors and
other signaling events usually cascade in a manner to direct that signal to the nucleus
(Leonard and others 1999; Roberts 1999). The convening of these signaling pathways at
the nucleus will then trigger the appropriate response such as modulating the timing of
mitosis, changing the pattern of gene expression, and/or initiating the apoptotic program,
leading to cell death. It is evident, then, that the nucleus is akin to the workings of a
microprocessor at the heart of a computer, and that the nuclear envelope plays a critical
role in defining the nuclear structural boundaries, and regulating the dynamics of complex
cellular responses.
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Overall Structure of The Nuclear Envelope
During interphase, the dual membranous structure of the nuclear envelope surrounds
the nucleus and is comprised of an inner (INM) and outer (ONM) nuclear membrane, the
outer being contiguous with the endoplasmic reticulum (Worman and Courvalin 2000).
The pore membranes (PM), where the nuclear pore complex (NPC) reside, form a
membranous connection between the INM and the ONM (Fig 1) (Ostlund and Worman
2003).

Figure 1 Schematic of nuclear envelope structure. (Adapted from: Ostlund C. Nuclear
envelope proteins and neuromuscular diseases. Muscle Nerve 2003;27:393-406)
Nuclear membranes: Dark Blue; Nuclear Pore Complexes: Yellow; Lamina: Red;
Chromatin: Light Blue.
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At the inner nuclear membrane periphery is an underlying network of intermediate
filament family proteins known collectively as the lamins, which provides a structural
meshwork for attachment of various transmembrane proteins, chromatin, and
transcription machinery (Fawcett 1966; Gerace and Burke 1988; Stuurman and others
1998). Examples of the most common proteins that interact at the inner nuclear
membrane periphery are the lamins, chromatin, lamina-associated polypeptides (LAP’s),
Lamin B Receptor (LBR), Otefin, MAN1, Emerin, Nesprin, barrier-to-autointegration factor
(BAF), and the transcription factors retinoblastoma (Rb), sterol regulatory element
binding protein (SREBP-1), Germ-cell-less (Gcl), and Oct-1 (Goldman and others 2002;
Goldman and others 2005) (Fig 2). The complexity of interactions that occur between the
scaffolding proteins, chromatin, transcription factors, and other proteins at the inner
surface of the inner nuclear membrane have profound implications on the overall
structural integrity of the cell, cell-cycle control, DNA replication, and regulation of gene
expression (Hutchison and Worman 2004). This complexity is governed by an intricate
control and regulatory system within the cell to control the disassembly and reassembly of
the entire nucleus during the mitotic program of higher eukaryotes (Ostlund and Worman
2003).

14

Figure 2 Interacting proteins at the inner nuclear membrane. (Adapted from: Goldman
RD. Nuclear lamins: building blocks of nuclear architecture. Genes Dev
2002;16:533-547)

The Structure and Nature of the Lamina
Like the plasma membrane, the structure and stability of the inner nuclear membrane
is responsive to a complex mesh of intermediate filament proteins (Fawcett 1966; Aebi
and others 1986; Fisher and others 1986). Specific to the nuclear envelope, this
underlying intermediate filament meshwork is comprised predominantly of the structural
proteins known as the lamins (Stuurman and others 1998). The intermediate filament
nature of the lamins make them similar to the structure of desmin, neurofilaments,
keratins, and vimentin, which are cytoplasmic intermediate filament proteins (Coulombe
15

and others 2001). The general structure of the lamins consisst of four conserved α-helical
coiled-coil rod domains characterized by heptad repeats of apolar residues (denoted 1A,
1B, 2A, and 2B), surrounded by head and tail globular domains (Hutchison and Worman
2004) (Fig 3).

Figure 3 Intermediate filament structure of the lamins. (Adapted from: Hutchison CJ.
A-type lamins: guardians of the soma? Nat Cell Biol 2004;6:1062-1067)

The lamins polymerize by forming obligate parallel dimers which interact at the
coiled-coil interface, which then assemble in an antiparallel geometry to form
higher-order intermediate filaments having a diameter of 10-13 nm (McKeon and others
1986). These filaments become laterally arranged into a two-dimensional matrix that
underlies the INM and interconnects the nuclear pore complexes (Aebi and others 1986).
The nuclear lamina tethers the nuclear face of the inner nuclear membrane to the
underlying chromatin maintaining overall nuclear architecture (Gotzmann and Foisner
1999) and has become known as a tensegrity element that maintains overall nuclear
stability by resisting tensile and mechanical deformation (Hutchison and Worman 2004).
16

A growing number or proteins have been shown to directly interact with the lamins, linking
the function of the lamins to much more dynamic and broader physiological processes
than that of the more traditional static structural role (Goldman and others 2002). The
inner nuclear membrane scaffold has been shown to mediate chromatin organization and
condensation (Paddy and others 1990), nuclear assembly and disassembly (Ulitzur and
others 1992), DNA synthesis (Spann and others 1997), transcriptional control (Dreuillet
and others 2002; Kumaran and others 2002; Lloyd and others 2002; Mancini and others
1994), and apoptosis (Rao and others 1996; Zhivotovsky and others 1997). This wide
spectrum of lamina associated events in vivo demonstrates that the lamina plays a much
larger role than predicted by the static structural model of lamin function.
The lamins are classified as either type A or type B depending on their behavior during
mitosis, physiochemical properties, and their tissue expression specificity (Gerace and
Blobel 1980; Krohne and Benavente 1986; Broers and others 1997). More specifically,
the A-type lamins are expressed mainly in highly differentiated cell types, are neutral, and
become soluble during the disassembly of the nuclear envelope during mitotic division. In
contrast, the B-type lamins are expressed ubiquitously in all cell types, are acidic, and
remain associated with membranous structures during lamina depolymerization and
mitotic breakdown of the nucleus. The A-type lamins A, A∆10, C, and C2 are all
differentially spliced products of the LMNA gene (Fisher and others 1986; Furukawa and
others 1994; McKeon and others 1986). The lamins classified as B-type are encoded by
two separate genes: Lamin B1 is the sole product of the LMNB1 locus, while Lamin B2
and Lamin B3 are products of the LMNB2 gene ( Pollard and others 1990; Biamonti and
others 1992; Furukawa and Hotta 1993). The tissue expression pattern of the LMNA
17

locus is primarily driven by the developmental program controlling embryogenesis and
organ differentiation (Rober and others 1989) and is found mainly in terminally
differentiated mammalian cell types. Lamin A is generally not found in nascent embryonic
cells, and does not become significantly expressed until after birth (Stewart and Burke
1987). In the adult, lamin A expression is completely absent in haematopoietic, immune,
and epithelial stem cells. However, in progeny of these stem cells, prelamin A expression
is observed after complete differentiation (Rober and others 1990). Lamin B1 and Lamin
B2, in contrast, are needed for cell survival and, consequently, are widely expressed in all
cell types, including adult stem cells (Harborth and others 2001; Steen and Collas 2001).
These observations along with the fact that the Lamin C2 and Lamin B3 isoforms are
found solely in germ-line cells (Furukawa and Hotta 1993; Furukawa and others 1994),
suggest that the lamins have a broad spectrum of tissue specific effects, the implications
of which are not fully understood yet. It has been hypothesized that the tissue specific
differential expression pattern of lamin A and C influences chromatin organization as to
maintain the differentiated state of the cell (Rober and others 1989).

Laminopathies
There are many disease phenotypes associated with altered nuclear envelope
function, collectively referred to as laminopathies (Burke and Stewart 2002; Mounkes and
others 2003). Most of the laminopathies discovered to date have been mapped to the
LMNA locus and, therefore, a great deal of research effort has focused on lamin A.
Mutations in LMNA can affect cardiac, muscular, skeletal, neural, or adipocyte tissues, or
any combination of these (Hutchison and others 2001). More specifically, mutations in the
18

LMNA gene are associated with at least 9 different human diseases including the
autosomal dominant form of Emery-Dreifuss muscular dystrophy (EDMD) (Bonne and
others 1999), dilated cardiomyopathy type 1A (DCM1A) with conduction system defects
(Fatkin and others 1999), limb-girdle muscular dystrophy 1B with atrioventricular
conduction disturbances (LGMD1B) (Muchir and others 2000), Dunnigan-type familial
partial lipodystrophy (FPLD) (Shackleton and others 2000), Charcot-Marie-Tooth disorder
type 2B1 (CMT2B1) (De Sandre-Giovannoli and others 2002), mandibuloacral dysplasia
(MAD) (Novelli and others 2002), restrictive dermopathy (RD) (Navarro and others 2004),
atypical Werner’s syndrome (Chen and others 2003), and Hutchison-Gilford progeria
syndrome (HGPS), a premature aging disorder that affects all tissues and results in
premature death (Eriksson and others 2003; Goldman and others 2004). The first genetic
model studied for laminopathies was LMNA null mice which die early at 8 weeks of age
and exhibit growth retardation, skeletal dysplasia, and cardiomyopathy, resembling
EDMD and DCM disorders in humans (Sullivan and others 1999). The first human
occurrence of a complete lamin A disruption resulted in death after premature birth
(Muchir and others 2003). This infant exhibited muscular dystrophy and severe joint
contractures and, thus, resembled the phenotype in LMNA-/- mice. Therefore, lamin A is
absolutely required for postnatal development and its absence is lethal. The
laminopathies associated with the less severe laminopathies are primarily point mutations
and premature truncations leading to altered nuclear function and morphology and are
found scattered across the entire length of the lamin A molecule (Burke and Stewart
2002) (Fig 4). An exception to this rule is the case of HGPS, in which a point mutation
G608G(GGC > GGT) within exon 11 causes a cryptic splice site to be activated, resulting
19

in the loss of 50 amino acids near the carboxy terminus (Eriksson and others 2003).
Interestingly, this 50 amino acid deletion removes the canonical endoproteolytic cut site
between Tyr646 and Leu647 but does not affect the presence of the CAAX box.
Presumably, this laminA∆50 mutant would possess a prenylated and carboxymethylated
carboxyl-terminal cysteine, identical to that of prelamin A. However, this has not been
experimentally verified to date.

Figure 4 Most common lamin A mutations resulting in disease. (Adapted from: Burke B.
Life at the Edge: The Nuclear Envelope and Disease. Nat Rev Mol Cell Biol
2002;3:575-585)

It is not immediately evident how mutations in a protein that is more or less
ubiquitously expressed in most terminally differentiated cells can give rise to phenotypes
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that affect such a wide array of different tissues. Currently, there are three major
hypotheses that attempt to explain the mechanisms responsible for lamin A associated
diseases: nuclear fragility; perturbations in cytoskeletal-nuclear interactions; and global
and/or specific gene expression changes (Burke and Stewart 2002; Mounkes and others
2003). A model in which lamin A malfunction causes nuclear fragility is an attractive
explanation for phenotypes associated with skeletal muscle and heart tissue disorders,
such a EDMD, LGMD, and DCM. In this model, shear stress due to mechanical use of the
muscle would eventually damage the nucleus and lead to cell death. This mechanical
fragility model is supported by the fact that more than 50% of lamin A mutations
associated with myopathy cause abnormal nuclear architecture when expressed in
myoblasts and fibroblasts (Ostlund and others 2001; Raharjo and others 2001).
However, this shear stress model fails to explain the tissue pathology of FPLD, a
phenotype that affects the function of adipocytes which is a tissue that does not
experience near the same amount of repetitive mechanical stress as muscle.
A more plausible model to explain the variety of tissue specific pathologies associated
with mutations in one protein is the gene-expression model. Lamin A has been found to
directly interact with a variety of gene-regulatory factors, including SREBP1 (Lloyd and
others 2002), MOK2 (Dreuillet and others 2002) , Rb (Mancini and others 1994), and BAF
(Gotzmann and Foisner 1999). As a specific example of this hypothesis, SREBP1 is a
transcription factor that activates genes involved in cholesterol biosynthesis, adipocyte
differentiation, and lipogenesis (Kim and Spiegelman 1996), and has been shown to
directly interact with the globulin like tail of lamin A (Lloyd and others 2002). Mutations in
Lamin A that cause FPLD bind SREBP1 with 25-40% less affinity (Lloyd and others
21

2002). Therefore, it becomes attractive to link FPLD to changes in adipocyte function due
to genes affected by altered SREBP1 function.
In addition to binding directly to specific gene regulatory factors, lamin A interacts
directly with naked DNA (Luderus and others 1994), histones (Taniura and others 1995),
and organizes heterochromatin (Kourmouli and others 2000). Gross disruptions in the
organization of chromatin, which is found in cells from EDMD patients, has the potential to
change global expression pattern of hundreds, or possibly, thousands of genes
(Ognibene and others 1999). In light of this, unraveling the fundamental causes for each
specific lamin A mutation linked to a laminopathy may only be possible through
experiments that measure global gene expression patterns using cDNA chip technology.
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The Processing Pathway of Prelamin A
Out of the 7 isoforms of lamin molecules, Lamin A exhibits a unique set of post
translational modifications prior to assembly into the nuclear lamina (Sinensky and others
1994b). Lamin A is first synthesized as a precursor, prelamin A, before fully maturing and
assembling into the nuclear lamina (Gerace and others 1984; Dagenais and others 1985;
Lehner and others 1986; Beck and others 1990). Similar to Lamin B, lamin A possesses a
canonical CAAX box (where C=cysteine, A = aliphatic amino acid, X = S, M, C, A, Q, L)
at the carboxyl-terminus of the molecule that undergoes three sequential
post-translational modifications (Vorburger and others 1989; Sinensky and others
1994b). More precisely, the series of post-translational modifications at the CAAX box
result in the prenylation of the cysteine sulfhydryl via a prenyltransferase, removal of the
AAX tripepeptide by a CAAX endopeptidase, and finally, carboxymethylation of the newly
exposed cysteinyl carboxy group via an isoprenylcysteine methyl transferase (ICMT)
(Sinensky and others 1994b) (Fig 5). Lamin B and Lamin A proceed through the same
first set of three modifications. However, unique to prelamin A, the last 15
carboxyl-terminal residues including the farnesylated and carboxymethylated cysteine of
prelamin A are removed in a second endoproteolytic step ( Weber and others 1989; Beck
and others 1990; Lutz and others 1992). This final endoproteolytic removal of the 2 kDa
prenylated peptide generates mature lamin A, which then is able to assemble into the
filamentous meshwork of the lamina underlying the nuclear envelope (Lutz and others
1992).
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Figure 5 The processing pathway of prelamin A. Prelamin A undergoes a unique series of
post translational modifications at the designated CAAX box, CSIM, including
farnesylation, AAX endoproteolysis, carboxymethylation at the farnesylated cysteine, and
a second endoproteolytic cleavage between tyrosine646 and leucine647, 15 residues
upstream from the farnesylated cysteine residue. This results in the production of mature
lamin A, along with the release of a ~2 kDA prenylated peptide.

In general, proteins with a CAAX box at the carboxy terminus can undergo an
isoprenoid lipid modification by either a farnesyl isoprenoid (15 carbon) when the X amino
acid is S, M, C, A, Q , or by a geranylgeranyl group (20 carbon) when the X amino acid is
leucine (Moores and others 1991; Seabra and others 1992; Armstrong and others 1995).
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The function, localization, and binding characteristics of a large variety of cellular proteins
can be modulated via a post-translational lipid modification at the c-terminus with a prenyl
moiety ( Hennekes and Nigg 1994; Fu and Casey 1999). Examples of proteins that are
modified by isoprenoid substituents are the nuclear lamins, fungal mating factors, protein
kinases, the Ras superfamily of GTPase proteins such as p21ras, phosphodiesterase
subunits, and heterotrimeric G proteins involved in receptor signaling (Glomset and
others 1990; Zhang and Casey 1996). The isoprenyl and subsequent carboxymethyl
modifications made to CAAX box proteins confers the ability to associate with
membranes either by a purely hydrophobic interaction with the phospholipid bilayer
(Black 1992; Rando 1996), or a prenyl-protein interaction with a membrane receptor
protein (Marshall 1993; Kisselev and others 1995). Examples of the latter mechanism is
the interaction of farnesylated lamin B with its inner nuclear membrane anchor, the lamin
B receptor (LBR) (Ye and Worman 1994), and the prenyl specific interaction of prelamin A
with NARF (Barton and Worman 1999).
Unlike lamin B, the lamin A precursor, prelamin A, is a unique example of a prenylated
protein in mammalian cells that undergoes an additional proteolytic step subsequent to
the canonical CAAX box modifications described above (Beck and others 1990). In the
process of maturation of prelamin A to lamin A, the last 18 carboxy terminal residues (15
residues upstream from the farnesylated cysteine) are removed in two endoproteolytic
steps, the second being an endoproteolytic cleavage between Tyr646 and Leu647(Weber
and others 1989). This endoproteolytic cleavage removes a ~2 kDa farnesylated peptide
and allows the mature lamin A to correctly assemble into the nuclear lamina . Removal of
this prenylated 2 kDa peptide is absolutely essential for assembly into the nuclear
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envelope. Evidence supporting this includes; incubating cells with lovastatin, which
inhibits isoprenoid biosynthesis, causes nonprenylated prelamin A to accumulate into
nucleoplasmic aggregates; incubating these cells with mevalonate causes this
aggregated prelamin A to convert to lamin A and properly assemble into the nuclear
envelope; and a lamin A construct missing this carboxyl-terminal farnesylated peptide,
when heterologously expressed in mammalian cells, properly assembles into the lamina
at the nuclear periphery (Lutz and others 1992). While it is necessary for prelamin A to be
farnesylated and carboxymethylated before the second endoproteolytic reaction can
occur to convert prelamin A to lamin A (Kilic and others 1997), the presence of this
prenylated peptide acts to block the polymerization of Lamin A into the intermediate
filament network.
Several lines of in vivo and in vitro evidence have demonstrated that the ability of the
second endoproteolytic reaction to occur depends on a completely modified CAAX box.
For example, when cells are incubated with mevinolin, a compound that specifically
reduces endogenous isoprenoid pools by inhibiting of isoprenoid biosynthesis, the
conversion of prelamin A to lamin A is abolished resulting in the accumulation of prelamin
A into nucleoplasmic aggregates (Beck and others 1990; Lutz and others 1992).
Experiments in which the CAAX box cysteine is mutated to abolish isoprenyl attachment
have also shown that prelamin A accumulates in nucleoplasmic aggregates, and that
conversion to lamin A is blocked (Holtz and others 1989; Hennekes and Nigg 1994).
Obviously, from these observations, it can be concluded that a prenylated substrate is
required for endoproteolytic processing of prelamin A. However, results from experiments
conducted in vitro with partially purified nuclear envelope fractions and a synthetic
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substrate mimicking the last 18 residues of prelamin A , are consistent with the conclusion
that prelamin A must not only be farnesylated, but also AAXed and carboxymethylated
before endoproteolysis can take place (Kilic and others 1997). In agreement with this is
the observation that ICMT -/- mice, which presumably should not be able to
carboxymethylate the prelamin A substrate, accumulate prelamin A in their cells (Bergo
and others 2002). Based on these observations, the substrate recognition constraints of
the endoprotease catalyzing the second reaction of prelamin A represents a novel and
highly specific interaction. Previous attempts in our lab to purify the endoprotease
catalyzing the second clip have been partially successful (Kilic and others 1999), but the
exact genetic identify of this enzyme has remained elusive. However, endoproteolytic
activity has been measured in nuclear envelope extracts using a model S-farnesyl,
cysteinyl methyl ester radioiodinated peptide corresponding to the carboxyl-terminal 18
amino acid residues of human prelamin A (Kilic and others 1997). Evidence that the
activity measured in a crude nuclear envelope fraction was due to the bona fide prelamin
A endoprotease included: activity was present in the nuclear envelope; endoproteolysis
occurred between Tyr646 and Leu647; substrate needed a farnesylated and
carboxymethylated cysteine for reactivity; and the activity was non competitively inhibited
by N-Acetyl farnesyl methyl cysteine (Kilic and others 1997; Kilic and others 1999).

Evidence for the Role of Zmpste24 in Prelamin A Maturation
The gene for the prelamin A endoprotease remained a mystery until genetic data
obtained from both yeast and mice provided specific information regarding its identity.
The first evidence was observed in the yeast with respect to the protein Ste24p, which
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was found to be the primary zinc-dependent metalloprotease responsible for the
endoproteolytically processing of the prenylated mating factor precursor, a-factor
(Fujimura-Kamada and others 1997). The proteolytic maturation of a-factor parallels that
of prelamin A in that it is first processed at the CAAX box by farnesylation, AAXing, and
carboxymethylation and then undergoes endoproteolysis 26 residues upstream from the
prenylated cysteine between a threonine and an alanine (Anderegg and others 1988;
Chen and others 1997). However, unlike prelamin A, a-factor undergoes a third
endoproteolytic step catalyzed by the Axl1p protease that cleaves 12 residues upstream
from the prenylated cysteine, producing the mature farnesylated dodecapeptide (Fig 6).
Ste24p catalyzes both the AAXing reaction and first endoproteolytic cleavage 26 residues
amino terminal to the prenylated cysteine, apparently mediated by a canonical
zinc-metalloprotease HEXXH active site (Fujimura-Kamada and others 1997; Boyartchuk
and Rine 1998; Tam and others 1998; Tam and others 2001).
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Figure 6 Processing pathway of the yeast pheromone, a-factor. (Adapted from: Burke B.
Life at the Edge: The Nuclear Envelope and Disease. J Cell Biol 1998;142:635-649)
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The similarities between the processing of prelamin A in mammals and a-factor in
yeast suggested the possibility that the human orthologue to Ste24p could play a role in
prelamin A maturation. The cloned and expressed human orthologue, Zmpste24
(Face-1), was shown to fully complement yeast Ste24p by possessing the ability to
process the prenylated a-factor at both the AAXing step and the first endoproteolytic
cleavage 26 residues amino terminal to the prenylated cysteine (Tam and others 1998;
Schmidt and others 2000). Although the function of a-factor in yeast is entirely different
from the function or prelamin A in mammals, the substrate processing similarities
between a-factor and prelamin A (three CAAX box modifications followed by an upstream
second endoproteolytic clip) suggests that the human orthologue to yeast Ste24p may be
the prelamin endoprotease.
Ste24 is a member of a larger group of zinc metalloproteinases of the M48 peptidase
family (MEROPS Database). This family of proteinases contains homologues from
bacteria (E.Coli, H. influenzae), fungi, higher eukaryotic multicellular organisms, and
mammals. (MEROPS Database). When comparing the yeast and mammalian forms of
Zmpste24, the human form of Zmpste24 is 36% identical and 51% similar to the S.
cerevisiae form (Tam and others 1998). They both share the common characteristics of

the canonical HEXXH zinc metalloproteinase domain, and 7 potential transmembrane
domains. Topologically, Ste24p has been shown to be localized to ER membrane in the
yeast, and is retained within the ER via a dilysine ER retention signal at the carboxy
terminus (Tam and others 1998). In contrast, human Zmpste24 does not contain an
identical form of this ER retention motif, but may possess a degenerate ER retention motif
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(lysines at positions 3 and 6 residues from the carboxy terminus). Mouse Zmpste24 has
been demonstrated to localize at the ER and nuclear envelope (Pendas and others 2002).
To elucidate the in vivo function of mammalian Zmpste24, various mice Zmpste24-/knockout strains have been generated and phenotypically characterized (Leung and
others 2001; Bergo and others 2002; Pendas and others 2002). It was observed that mice
deficient in Zmpste24 exhibited skeletal abnormalities, muscle weakness, growth
retardation associated with premature death, dilated cardiomyopathy, and lipodystrophy,
which are all phenotypes associated with defects in lamin A that cause human
laminopathies (Bergo and others 2002; Pendas and others 2002). Upon evaluating the
fate of prelamin A in fibroblasts derived from Zmpste24-/- mice, it was observed that
prelamin A accumulates in these cells without conversion to mature lamin A.
Furthermore, membranes from these cells were inactive, compared to wild-type, in
carrying out the N-terminal processing of yeast a-factor, suggesting that Zmpste24, like
Ste24p, possesses a farnesylation dependent endoproteolytic activity (Leung and others
2001). The results from the Zmpste24 knockout experiments in conjunction with the yeast
data concerning a-factor led to the obvious hypothesis that prelamin A is the physiological
substrate for human Zmpste24.
Assigning Zmpste24 as a prelamin A endoprotease had one major inconsistency with
previous data from in vitro experiments on crude nuclear envelope fractions. More
specifically, the enzymatic activity in the nuclear envelope catalyzing the second
endoproteolytic cleavage could be abolished by serine protease inhibitors (Kilic and
others 1999). However, all endoproteolytic activity of Ste24 and human Zmpste24 on the
a-factor substrate could be inhibited by the zinc metalloprotease inhibitor,
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1,10-orthophenanthroline (Schmidt and others 2000; Leung and others 2001; Tam and
others 2001). Both yeast Ste24 and human Zmpste24 contain a canonical HEXXH (X =
any amino acid) domain, which is a characteristic of the gluzincin family of zinc
metalloproteases (Hooper 1994). Fundamentally, serine proteases function by a
completely different catalytic mechanism than zinc metalloproteases. In the superfamily
of serine proteases, the three residues that form the catalytic triad (Ser, His, and Asp),
form a charge relay system to hydrolyze the peptide bond (Rawlings and Barrett 1994;
Barrett and Rawlings 1995). Hydrolysis in a zinc metalloproteinase is catalyzed by a Zn+2
divalent cation coordinated by the histidine and glutamic acid in the HEXXH motif (Hooper
1994). Because endoproteolytic activity on a crude nuclear envelope fraction is sensitive
to the serine protease inhibitors aprotinin, PMSF and isocoumarin, and yeast Ste24p is
sensitive to the Zn+2 chelator, Opa, it didn’t seem likely that Zmpste24 could be the
endoprotease catalyzing the second reaction. However, it could be argued from the
genetic data that the sole responsibility of Zmpste24 is to catalyze the first AAXing
reaction, and that some other serine like endoprotease performs the second reaction.
This possibility could not be ruled out from the Zmpste24-/- genetic data from mice
because the accumulation of prelamin A in mouse fibroblasts could simply be due to the
failure of the endoprotease to convert prelamin A to lamin A because of an unfully
processed CAAX box. In other words, if the function of Zmpste24 is solely to AAX
prelamin A, then a lack of Zmpste24 activity in the cell would necessarily cause the
accumulation of a non-AAXed and, thus, non carboxymethylated prelamin A molecule.
The experimental observations that ICMT-/- mice accumulate prelamin A (Bergo and
others 2002) along with in vitro data using model prelamin A peptides (Kilic and others
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1997), conclusively demonstrate that a fully processed CAAX box is needed for the
second endoproteolytic activity. Therefore, the phenotypic manifestations of Zmpste24-/mice could simply be due to a lack of the first endoproteolytic AAXing reaction on
prelamin A.

Diseases Associated with Zmpste24
The first phenotypic observations associated with impaired Zmpste24 function came
from the generation of Zmpste24 knockout mice. Interestingly, the first Zmpste24-/- mice
were reported to exhibit no phenotype and were not recognizably different from wild type
control mice (Leung and others 2001). This first observation was shortly thereafter
supplanted by a second group who published a paper demonstrating that Zmpste24-/mice exhibit phenotypes akin to the manifestations seen in laminopathies (Pendas and
others 2002). Five months later, the group that published the first Zmpste24-/- paper that
showed no phenotype, reported in a second revised publication that Zmpste24-/- mice did,
indeed, have a laminopathy related phenotype, but that they were reluctant to report this
in their first publication due to the possibility that the neomycin cassette used in Zmpste24
gene disruption was altering the transcription of neighboring genes (Bergo and others
2002). The common set of phenotypes from both groups show that Zmpste24-/- mice
exhibit retarded growth curves, premature death at 20 weeks, alopecia, muscle
weakness in the limbs, low plasma glucose levels, and abnormal gait, and kyphosis
(exaggerated outward curvature of the spine). However, Pendas also reported that
Zmpste24-/- mice manifest other pathologies such as dilated cardiomyopathy, ventricular
thinning, secondary liver disease, growth plate dysplasia in the femur and tibia, and a
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partial lypodystrophy characterized by loss of subcutaneous fat, phenotypes that were not
seen in the Zmpste24-/- mice studied by Bergo. In contrast, the mice generated by Bergo
and others showed reduced cortical and trabecular bone volumes in conjunction with
spontaneous bone fractures similar to those seen in osteogenesis imperfecta. This
skeletal myopathy was not reported for the Zmpste24-/- mice investigated by Pendas.
Because these phenotypes were similar to those seen in human and mice lamin
disorders, Pendas studied the structure of the nucleus using confocal fluorescent
microscopy using typical nuclear envelope markers (Lamin A/C, Lamin B1, and emerin).
While wild type cells showed a typical ovoid appearance, cells from Zmpste24-/- mice
showed abnormal nuclear morphological perturbations at the nuclear envelope
resembling membranous herniations at the nuclear wall. The fact that the set of
abnormalities seen in these mice resemble those of traditional laminopathic disorders
prompted Pendas to study the processing of prelamin A in fibroblasts from these mice.
Western blots with prelamin A and lamin A/C antibodies on cell lysates derived from
Zmpste24 -/- mice demonstrated that the premature 74 kDa prelamin A form accumulates
at the expense of the presence of the 72 kDa mature form. Accumulation of prelamin A at
the nuclear periphery in Zmpste24-/- cells was also verified by indirect
immunofluorescence using prelamin A specific antibodies. As a final demonstration that
prelamin A was the in vivo substrate for Zmpste24, fibroblasts from Zmpste24-/- mice
were transfected either with prelamin A, or both prelamin A and Zmpste24. Cotransfection
with Zmpste24 restored endoproteolytic processing of prelamin A to the lamin A mature
form. The results from these experiments were the first that generated the hypothesis that
prelamin A is the in vivo substrate for Zmpste24. It is important to note that this hypothesis
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was not tested in vitro, nor was the accumulated precursor prelamin A protein
characterized to determine if farnesylation, AAXing, or carboxymethylation took place at
the CAAX box. Because these experiments were not carried out, it was not possible at
that time to assign Zmpste24 as responsible for the first, second, or both endoproteolytic
reactions. There also remained the possibility that Zmpste24 was not either of these
endoproteases but was rather a membrane anchor or an upstream activator of other
proteases involved in the maturation of prelamin A.
In humans, Zmpste24 mutations have been linked to a number of lethal and non lethal
disorders. The first to be discovered was linked to a rare autosomal recessive disorder
known as mandibuloacral dysplasia (MAD: OMIM 608612 and OMIM 248370), which was
previously only linked to a Arg527His mutation in the LMNA gene (Agarwal and others
2003). Agarwal demonstrated that patients with MAD could also possess compound
heterozygous mutations in the gene for Zmpste24 in which Zmpste24 from one allele is
prematurely truncated due to a Phe361fsX379 mutation, and the other allele carries a
Trp340Arg substitution adjacent to the HEXXH motif. MAD is characterized by
underdevelopment of skeletal features, abnormally small lower jaw, degeneration of
bone (acro-osteolysis), atrophy of the skin, scarce brittle hair, mottled skin pigmentation,
type B lipodystrophy, and, in some cases, progeroid appearance (Schrander-Stumpel
and others 1992; Agarwal and others 2003). From the fact that mutations in both
Zmpste24 and Lamin A could manifest the same phenotypic characteristics, Agarwal
hypothesized that MAD associated with mutations in Zmpste24 was caused by abnormal
processing of prelamin A. Although the homozygous Arg527His mutation in lamin A has
been shown to lead to the accumulation of the prelamin A precursor (Capanni and others
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2005), accumulation of prelamin A from patients with Zmpste24 associated MAD has not
been experimentally tested. Interestingly, each Zmpste24 mutation was tested for
processing of a-factor in yeast mutants incapable of producing mature a-factor. The
results showed that the prematurely truncated form of Zmpste24 was incapable of
complementing this defect, while the Trp340Arg mutant was able to restore processing of
a-factor less efficiently than wild type Zmpste24. Therefore, if these results can be
correlated to the processing of prelamin A, then it can be expected that patients harboring
both of these Zmpste24 mutations would be able to process prelamin A to some extent.
However, the rate of conversion may be so inefficient that some amount of prelamin A
accumulation may occur in these cells.
Zmpste24 mutations have also been linked to a lethal disorder known as restrictive
dermopathy (RD: OMIM 275210). RD is also known as lethal tight skin contracture
syndrome and is characterized by slow growth during gestation, tight translucent skin,
sever contractures of the joints, craniofacial abnormalities, epidermal hyperkeratosis, and
death following birth due to pulmonary hypoplasia and restricted movement (Navarro and
others 2004). RD has been linked to both heterozygous mutations in prelamin A and
homozygous loss of function mutations in Zmpste24 (Navarro and others 2004; Navarro
and others 2005). More precisely, patients have been observed to carry a heterozygous
de novo point mutation in lamin A that results in the loss of exon 11. Patients carrying this
type of mutation show the accumulation of a truncated form of prelamin A. Patients with
RD have also been found to carry a homozygous 1085dupT mutation (encoding
Phe361fsX379, identical to the MAD mutation) in Zmpste24, leading to a prematurely
terminated inactive form of Zmpste24. Cells from RD patients with this Zmpste24
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mutation accumulate prelamin A and show abnormal nuclear morphology along with
mislocalization of lamin associated proteins (Navarro and others 2004). Therefore, the
correlation between prelamin A maturation and Zmpste24 in RD patients argues that
Zmpste24 is involved in the processing of prelamin A.
Both RD and MAD can arise from mutations in lamin A or Zmpste24. In fact, the same
premature Zmpste24 truncation mutation is observed in both of these disorders. This
raises a puzzling question; how does the same mutation in one gene give rise to to
different phenotypes? This peculiarity is compounded by the fact that RD is lethal, but
MAD is not. The most probable explanation is that MAD patients have only been identified
with compound heterozygous mutations for Zmpste24, with one allele being partially
functional. However, in RD patients, both alleles for Zmpste24 are truncated, resulting
from a recessive inheritance. Therefore, if prelamin A is indeed the substrate for
Zmpste24, then the major difference between RD and MAD cells should be the level of
unprocessed prelamin A present. More specifically, in cells derived from patients with RD
where both alleles of Zmpste24 are disfunctional, a relatively high level of prelamin A
should be observed, and this is, indeed, what is observed (Navarro and others 2005). In
contrast, in cells derived from MAD patients a lower accumulation of prelamin A should
result because one partially functional copy of Zmpste24 is present. This line of reasoning
leads to the hypothesis that the precursor protein, prelamin A, is relatively toxic to cells in
a dose dependent manner, because RD patients with the highest level of prelamin A die
shortly after birth, while patients with MAD live a normal life span. This hypothesis is
supported by experiments that compared the phenotype of Zmpste24 -/- mice and
Zmpste24-/- LMNA-/+ mice that produce half the normal level of lamin A (Fong and others
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2004). The results from this experiment revealed that by reducing the amount of prelamin
A that accumulates due to loss of Zmpste24 function by a factor of 2 results in a total loss
of the Zmpste24-/- induced phenotype.
The effects of siRNA induced Zmpste24 knockdown in cell culture has been studied in
HeLa cells and has supported the hypothesis that prelamin A accumulation is toxic
(Gruber and others 2005). More specifically, upon induction of Zmpste24 knockdown,
HeLa cells abruptly stop cell division and can 1) directly proceed through apoptosis or 2)
form dysmorphic hyperlobulated nuclei that accumulate unprocessed prelamin A at the
periphery of the nuclear envelope. In addition, if lamin A is knocked down prior to
Zmpste24 knockdown, or if the experiments are repeated in HL60 cells that lack
endogenous lamin A, the apoptotic or dysmorphic phenotype is completely absent. This is
in agreement with the experiments performed in Zmpste24-/- LMNA+/- mice that show that
the toxicity of prelamin A is dose dependent.
This prelamin A toxicity hypothesis is supported by the fact the prelamin A also
accumulates in cells from patients bearing certain mutations in the lamin A protein itself.
Prelamin A has been observed to accumulate in patients that possess the following lamin
A mutations: R527H resulting in MAD; R482L resulting in FPLD ; and S143F resulting in
atypical WS (S143F) (Capanni and others 2005). Also, internally truncated forms of
prelamin A that still possess the CAAX box have been shown to accumulate in HGPS
(Goldman and others 2004) and RD (Navarro and others 2004). Interestingly, in all of
these disorders lipodystrophy is a common phenotype, and experiments have shown that
the accumulation of prelamin A, but not lamin A, in MAD, FPLD, and WS cells sequesters
the adipogenic transcription factor SREBP to the nuclear envelope and down regulates
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PPARγ, a transcription factor activated downstream by SREBP (Capanni and others
2005). This same in vivo data regarding the function and localization of SREBP can be
reproduced in wild type cells that were induced to accumulate prelamin A by treating them
with mevinolin, an inhibitor or isoprenoid biosynthesis. Therefore, in addition to high
doses of prelamin A being toxic to cells, it has been demonstrated that defective prelamin
A processing can alter the activity of specific transcription factors. Therefore, it would be
expected that pathologies associated with mutations in the endoprotease that processes
prelamin A would phenocopy laminopathies linked with the accumulation of prelamin A.
This prediction is supported by the fact that RD (Navarro and others 2005), MAD
(Agarwal and others 2003), along with progeroid like symptoms (Shackleton and others
2005) have now all been linked not only to mutations in LMNA but also mutations in
Zmpste24.
Overall, this phenotypic data argues that prelamin A is the in vivo substrate for
Zmpste24, and that the farensylated 2 kDa peptide representing the last 15
carboxyl-terminal residues of prelamin A is somehow toxic to cells. In light of this, it may
be possible to account for the wide ranging differences in phenotypic manifestations
among most of the known laminopathies by considering the fact that the precise
expression level of prelamin A in each cell type varies in the population due to inherit
genetic background differences. Therefore, the pathology of lamin A disorders is
expected to exhibit individual variation in that the manner in which the disease manifests
itself is based primarily on two factors: the rate at which prelamin A is being expressed in
each tissue; and the rate at which other modifications take place, including
endoproteolysis, to convert prelamin A to lamin A. The balance of these two rates
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ultimately determines the amount of prelamin A that accumulates in any given cell, and
the amount of prelamin A present in the cell, in turn, controls the severity and/or type of
phenotypic manifestation. A dose dependent hypothesis of prelamin A function is
attractive, for it offers an explanation towards the multifaceted array of tissue specific
disorders associated with disfunction of a single protein, prelamin A. However, the exact
biochemical mechanism(s) behind the downstream effects of prelamin A accumulation is
inherently complex due to the many functions, interactions, and binding partners
presently known for lamin A.

Specific Aims
Although the mouse knockout data and the observation that human diseases
associated with Zmpste24 malfunction resemble laminopathy like phenotypes build a
strong case for Zmpste24 being the first, second, or both endoproteases involved in
prelamin A maturation, this can not be conclusively demonstrated unless Zmpste24 is
tested against the prelamin A substrate in vitro. In all of the background experiments
reported, an in vitro experiment to test the hypothesis that Zmpste24 is the prelamin
endoprotease has not been conducted. Therefore, the major aim of this body of work was
to demonstrate the precise role of Zmpste24 in prelamin A endoproteolytic processing. To
complete this goal, two different substrates were employed to monitor each
endoproteolytic reaction in the processing pathway of prelamin A. To assay AAXing, we
synthesized a farnesylated tetrapeptide that modeled the carboxyl-terminal end of
prelamin A, and followed its conversion upon incubation with recombinant Zmpste24. We
also recombinantly expressed a fully processed (farnesylated, AAXed, and methylated)
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carboxyl-terminal fragment of prelamin A and employed this as a substrate to monitor the
second endoproteolytic cleavage. The generation of recombinant active Zmpste24, which
contains 7 transmembrane domains, and the substrate prelamin A, which possesses a
complex series of post translational modifications, is obviously not trivial, and this may
explain the lack of such an experiment in the literature to date.
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CHAPTER 2
MATERIALS AND METHODS

Materials
The BacPak8 baculovirus protein expression system was from Clontech and
employed Sf21 (Spodoptera frugiperda) insect cells from Invitrogen. Sf21 cells were
grown in Grace’s Insect Medium (Gibco) containing 10% heat-inactivated FBS (Gibco),
0.1% Pluronic F-68 (Cellgro), 10 mg/ml Gentamicin (Gibco), supplemented with 500 mg/L
CaCl2, 2800 mg/L KCl, L-glutamine, 3330 mg/L lactalbumin hydrolysate, and 3330 mg/L
yeastolate. CHO-K1 cells were cultured in Ham's F-12 medium containing 5% fetal calf
serum, 100 units/ml penicillin, and 100 µg/ml streptomycin (F12FC5). Antibodies used in
this study included: mouse monoclonal anti-Zmpste24 (recognizing residues 56-76) a gift
from S. Young (Gladstone Institute); rabbit polyclonal anti-Zmpste24 (recognizing
residues 440-455) (Abgent); mouse monoclonal anti-(His)6 (BD Biosciences);
goat-anti-mouse IgG-HRP (Pierce); goat-anti-rabbit IgG-HRP (Santa Cruz
Biotechnology); donkey-anti-goat IgG-HRP (Santa Cruz Biotechnology); mouse
monoclonal anti-farnesyl (Sigma), goat polyclonal anti-lamin A (Santa Cruz
Biotechnology), rabbit polyclonal anti-prelamin A (Sinensky and others 1994a) and
anti–mouse IgG Texas red-conjugated antibody (Biomeda). Radioactive isotopes
included: [35S]-methionine (specific activity 1175 Ci/mmol; ICN Biomedicals); 5-R, S-[3H]
mevalonate (specific activity 60 Ci/mmol; American Radiolabeled Chemicals, St. Louis),
[3H]-methyl-S-adenosylmethionine (specific activity 66.8 Ci/mmol; ICN Biomedicals),
[3H]-FPP (specific activity 20 Ci/mmol; American Radiolabeled Chemicals, St. Louis).
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Cloning of Prelamin A, Zmpste24, and ERp57
The template construct for prelamin A was a kind gift from H.J. Worman (Columbia
University) and included the C-terminal residues 389-664 of human prelamin A
(prelaminAct) cloned into the vector pBFT4 (Barton and Worman 1999). We performed
PCR directed cloning of this insert fused to a (His)6 tag at the N-terminus using two
separate PCR reactions: The first stage used the forward primer
5’-ATGGCTCATCATCATCATCATCATCTGTCCCCCAGCCCTACCTC-3’ and the
reverse primer 5’-GCGAATTCTTACATGATGCTGCAGTTCT-3’. The product from this
PCR was then amplified with forward primer
5’-TAGGATCCACCATGGCTCATCATCATCATCATCATCTGT-3’ and the same reverse
primer as in the first reaction. This product was directionally cloned into the (5’)-BamH1
(3’)-EcoR1 restriction sites of the pBacpak8 baculovirus expression vector (Clontech).
Translation of this sequence in the Sf21 baculovirus system resulted in the following
protein sequence containing an N-terminal (His)6 tag fused to residues 389-664 of
prelamin A:
MAHHHHHHLSPSPTSQRSRGRASSHSSQTQGGGSVTKKRKLESTESRSSFSQHART
SGRVAVEEVDEEGKFVRLRNKSNEDQSMGNWQIKRQNGDDPLLTYRFPPKFTLKAG
QVVTIWAAGAGATHSPPTDLVWKAQNTWGCGNSLRTALINSTGEEVAMRKLVRSVTV
VEDDEDEDGDDLLHHHHGSHCSSSGDPAEYNLRSRTVLCGTCGQPADKASASGSGA
QVGGPISSGSSASSVTVTRSYRSVGGSGGGSFGDNLVTRSYLLGNSSPRTQSPQNCS
IM

43

To make the RSY RLG mutant (Y647 Æ R647) of prelamin A, we introduced a point
mutation using the Quickchange Kit (Stratagene) into this prelaminAct/pBacpak8
construct with the primer 5’-GTCACCCGCTCCTACCGCCTGGGCAACTCCAG-3’ along
with its complimentary sequence.
Zmpste24 was cloned into the (5’)-Nhe1 (3’)-BamH1 site of the pcDNA3.1 construct
using RT-PCR on HeLa RNA (Stratagene). The forward primer was
5’-GCGGCTAGCATGGGGATGTGGGCATCGCT-3’ and the reverse primer was
5’-GCGGGATCCGGACATCTCAGTGTTGCTTCATAG-3’. Zmpste24 was then
subcloned using this as the template into pBacpak8 with the first set of primers being
5’-CATCATCATCATCATCATATGTGGGCATCGCTGGAC-3’ (Forward) and
5’-GTGACGCCCGGGTCAGTGTTGCTTCATAGTTTTCAAAGC-3’ (reverse) and the
second set being
5’-GCTGGCTCGAGACCATGGGCCATCATCATCATCATCATATGTGG-3’ (forward) and
the same reverse primer as the first reaction. The PCR product was directionally cloned
into pBacpak8 using the (5’)-Xho1 (3’)-Xma1 restriction sites. Translation of this
sequence in the Sf21 baculovirus system resulted in the following protein sequence
containing an N-terminal (His)6 tag fused to residues 1-475 of Zmpste24:
MGHHHHHHMWASLDALWEMPAEKRIFGAVLLFSWTVYLWETFLAQRQRRIYKTTTHV
PPELGQIMDSETFEKSRLYQLDKSTFSFWSGLYSETEGTLILLFGGIPYLWRLSGRFCG
YAGFGPEYEITQSLVFLLLATLFSALTGLPWSLYNTFVIEEKHGFNQQTLGFFMKDAIKK
FVVTQCILLPVSSLLLYIIKIGGDYFFIYAWLFTLVVSLVLVTIYADYIAPLFDKFTPLPEGK
LKEEIEVMAKSIDFPLTKVYVVEGSKRSSHSNAYFYGFFKNKRIVLFDTLLEEYSVLNKDI
QEDSGMEPRNEEEGNSEEIKAKVKNKKQGCKNEEVLAVLGHELGHWKLGHTVKNIIIS
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QMNSFLCFFLFAVLIGRKELFAAFGFYDSQPTLIGLLIIFQFIFSPYNEVLSFCLTVLSRRF
EFQADAFAKKLGKAKDLYSALIKLNKDNLGFPVSDWLFSMWHYSHPPLLERLQALKTM
KQH

The ERp57 served as a mock infected control to emulate protein expression changes
due to viral infection. ERp57 containing a (His)6 tag at the N-terminus was cloned similarly
using the first set of primers
5’-ATGGCTCATCATCATCATCATCATCGCCTCCGCCGCCTAGC-3’ (forward) and
5’-GCACGCGAATTCTACTGCTTTAGAGATCCTCCTG-3’ (reverse). The second
amplification used
5’-GCTACTGGATCCATGGCTCATCATCATCATCATCATCGCCTC-3’ (forward) and the
same reverse primer as the first reaction. This was cloned into the (5’)-BamH1 (3’)-EcoR1
site of pBacPak8. Each construct was verified for accuracy by sequencing. Recombinant
high-titer baculovirus stock was produced for prelaminAct, Zmpste24, and ERp57
according to the manufacturer’s protocol (Clontech) in the Sf21 baculovirus expression
system.

Cloning of Zmpste24 Mutants and Truncations
The (His)6-WT Zmpste24 in pBacpak8 was used as the template plasmid in the
QuickChange Site Directed Mutagenesis Kit (Stratagene). Six mutants were generated
from this wild type plasmid and are designated: ∆HEXXH, H335A, Y379Stop, L290Stop,
P230Stop, and C109Stop. Primers were designed to introduce these mutations into the
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WT sequence and were used in the QuickChange PCR reaction according to the
manufacturer’s protocol. The primers used to introduce these mutations are as follows:

∆HEXXH

5’-CTCGCTGTACTAGGCTGGAAGTTGGGACATAC-3’

H335A

5’-CTCGCTGTACTAGGCGCCGAACTGGGGCACTGG-3’

Y379Stop

5’-TTTGCTGCATTTGGTTTTTAGGATAGCCAACCCACTC-3’

L290Stop

5'-ACTAGAAGAGTACTCTGTATAGAACAAAGACATCCAGGAGG-3'

P230Stop

5'-TGACAAATTCACACCTCTGTAGGAGGGAAAGCTTAAAGAAG-3'

C109Stop

5'-GACTTTCTGGACGGTTCTAGGGTTATGCTGGCTTTGG-3'

For each of these sense primers, anti-sense primers were designed as well, which
correspond to the reverse complement of these sequences. Each of these mutant
plasmids was introduced into the Sf21 baculovirus system for protein expression using
the same protocol as the wild type sequence.

Baculovirus Expression Protocol
Spodoptera frugiperda (Sf21) (Invitrogen) cells diluted to 1 x 106 cells/ml, were grown
in log phase growth in Grace’s Insect Medium (Gibco) containing (10% FBS-heat
inactivated, 0.1% Pluronic F-68, 10 mg/ml Gentamicin), were infected with high-titer
recombinant baculovirus expressing either human Zmpste24, PrelaminAct or ERp57
(mock transfected control) at a multiplicity of infection of 10. Subsequently, 72 hours
post-infection, cells were pelleted and stored at -80oC. These Sf21 cell pellets were then
used for producing enzyme enriched membranes or purified substrate.
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Preparation of Enzyme Enriched Membranes
Sf21 cells expressing either Zmpste24 or Erp57 (mock transfected control) were
resuspended in 50 mM Tris-HCl pH 7.0 and disrupted by either sonication or a French
press at 1000 psi. Nuclei and debris were removed by centrifugation at 500Xg for 5 min
and membranes were then pelleted by centrifugation at 200,000Xg for 1.5 h. The
membrane pellet was then washed with 50 mM Tris-HCl and centrifuged multiple times to
remove all cytosolic components and possible sources of protease activity from the
cytosolic fraction. Membranes were resuspended in 50 mM Tris-HCl and stored frozen at
–80°C in multiple aliquots (Otto and others 1999). Protein content was determined
according to the method of Lowry using the DC Protein Assay Reagent Kit (Biorad).

Immunoblotting
Protein samples were separated by SDS/PAGE and then electroblotted onto a PVDF
membrane (Immobilon-P Millipore). The membranes were saturated with 5% (wt./vol.)
nonfat dry milk in TBST [50 mM Tris·HCl (pH 8.0), 138 mM NaCl, 2.7 mM KCl, 0.05%
Tween 20] (Sigma), then incubated 1 hr. with the primary antibody of interest. The
membranes then were washed with TBST and incubated for 1 hr. with either
goat-anti-mouse IgG-HRP (with anti-Zmpste24 (residues 56-76) or anti-(His)6 as
primary), goat-anti-rabbit IgG-HRP (with anti-prelamin A or anti-Zmpste24 (residues
440-455) as primary) or anti-goat IgG-HRP (with anti-lamin A as primary). Detection was
performed with the Enhanced Chemiluminescence (ECL) kit (Pierce).
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Metabolic Labeling of PrelaminAct
After infection with baculovirus (60 hours post-infection), Sf21 cells were labeled
either 4 hours with [35S]-methionine (100 mCi/ml, specific activity 1175 Ci/mmol) or 16
hours in growth medium containing 5-R, S-[3H]-mevalonate (125 mCi/ml, specific activity
60 Ci/mmol). During mevalonate labeling, insect cells were treated with lovastatin (10
mg/ml) (Tocris). After labeling the Sf21 cells were harvested, sonicated in lysis buffer (50
mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0), separated into membrane and
cytosolic components, and purified using Ni-NTA beads (Qiagen). The [3H]-mevalonate
and [35S]-methionine labeled prelaminAct fractions were separated on a 4-12% gradient
(MES) and 10% (MOPS) SDS-PAGE gel system (Invitrogen), respectively. Dried gels
were visualized by either fluorography or phosphorimager.

Purification of (His)6 Tagged Prelamin A and Zmpste24
Sf21 cells, expressing recombinant protein, were subject to lysis by sonication in a
lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0, 1mg/ml E-64).
Membrane and cytosol fractions were separated by centrifugation (100,000 X g for 1
hour). Membrane bound proteins were solubilized in 1% NP-40 (prelamin A) or 1.5% octyl
glucoside (Zmpste24), homogenized, and insoluble material removed by centrifugation at
100,000Xg. Cytosolic and membrane fractions were incubated for 2h at room
temperature with Ni-NTA beads in lysis buffer. After incubation, the beads were washed
with 8 vol. of lysis buffer containing 20 mM imidazole and then eluted with 1 volume of
lysis buffer containing 250 mM imidazole for 15 minutes. Samples were analyzed by
SDS-PAGE and immunoblot.
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Immunoprecipitation with anti-Farnesyl
Ni-purified [35S]-Met labeled prelamin Act was immunoprecipitated by incubation with
an anti-farnesyl antibody in 30 mM HEPES (pH 7.5), 10 mM NaCl, 5 mM MgCl2, 25 mM
NaF, 1 mM EDTA and 5% Nonidet P-40 (vol./vol.) for 16h at 4 ˚C. The complexes were
isolated on protein A-Sepharose beads. The beads were washed, the immunoprecipitate
was resuspended in 0.1N NaOH and incubated for 30 min at 30 ˚C to release precipitated
protein. The pH of the eluted sample was neutralized by the addition of 0.1 M HEPES free
acid. The products were separated on 10% SDS-PAGE (Invitrogen), transferred to PVDF
membrane, and then visualized with a FUJIFILM FLA-5000 Phosphorimager (Fujifilm
Medical Systems USA, Inc.).

MALDI-TOF Mass Spectrometry
Proteins were purified by SDS-PAGE, visualized by Coomassie staining and the
appropriate bands excised. The isolated proteins were treated with iodoacetamide and
digested with trypsin. MALDI-TOF was with a PerSeptive Voyager DE-RP mass
spectrometer in the linear or reflector mode. This was performed by Mary Ann
Gawinowicz at the Protein Chemistry Core Facility at Columbia University.

Mammalian Cell Culture and Transfection
For transient transfections, CHO-K1 cells were seeded at 3 X 105 cells/well in a 6-well
culture plate and transfected with the Zmpste24/pcDNA3.1 construct using the
Stratagene GeneJammer transfection reagent according to the manufacture's protocol.
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Indirect Immunofluorescence
Transiently transfected CHO-K1 cells on glass coverslips were briefly rinsed in
phosphate buffered saline (PBS) then fixed with 4% formaldehyde in PBS (pH 7.4) for 15
min at 20 ˚C. Following three washes in PBS, the cells were permeabilized with 0.2%
Triton X-100 in PBS for 5 min on ice, quickly washed, and blocked with 10% BSA in PBS
for 5 min on ice. The coverslips were incubated for 1h at room temperature with mouse
monoclonal anti Zmpste24 antibody (diluted 1/500) developed against residues 56-76.
Cells were then washed and incubated at room temperature for 1h with anti–mouse IgG
Texas red-conjugated antibody (diluted 1/500). Images were obtained by digital
deconvolution of 10-slice stacks acquired on a Nikon Diaphot 200 microscope equipped
with a Photometrics Sensys cooled CCD digital camera or Nikon D100 Oncor Z-Drive
using Oncor Image Software.

Farnesylation of CSIM Tetrapeptide
Each reaction mixture contained, in a total volume of 100 µl, 50 mM Tris chloride (pH
7.5), 50 µM ZnCl2, 3 mM MgCl2, 20 mM KCl, 1 mM DTT, 0.2% (v/v) octyl β-D-glucoside
with 10 µM farnesyl pyrophosphate 100 µM Ac-CSIM-OH (Sigma Genosys), and 0.3 µg of
farnesyltransferase (Sigma) (Goldstein and others 1991). When radiolabeled substrate
was prepared, [3H]-FPP (20Ci/mmol) was substituted for cold FPP in the reaction above
(final concentration of 1µM). After 1h incubation at 37 ˚C, the reaction was terminated by
the addition of 0.1 µl of concentrated HCl. Ac-(farnesyl)CSIM-OH was extracted with ethyl
acetate (2 x 100 µl), dried under N2 and dissolved in ethyl acetate. To confirm purity,
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reaction products were separated by TLC on plastic-backed Silica Gel G thin layer sheets
(20 x 20 cm, Whatman) developed with chloroform:acetone:methanol:acetic acid
(70:15:8:2). The farnesylated product was visualized by brief staining with iodine vapor
(cold substrate), or by fluorography ([3H]-FPP labeled substrate). Fluorography was
accomplished by spraying the TLC plates with Enhance (Perkin Elmer) and exposing the
film to Kodak-AR film in the presence of an intensifying screen.

Base Release Assay for AAXing Activity
The AAXing proteolysis mixtures were conducted in a total volume of 20 µl in buffer
[250 µM zinc acetate, 200 mM NaCl, and 200 mM HEPES (pH 7.5)] with either 2 µM
farnesylated a-factor or 2 mM Ac-(farnesyl)CSIM-OH (see above) and 30 µg of a
membrane preparation from insect cells expressing either Zmpste24 or Erp57. After
incubation at 30 ˚C for 25 min, reactions were terminated by heating to 95 ˚C for 1 min.
Methylation reactions were then initiated by the addition of premixed 100 µg E. coli lipid
and 0.13 µg purified Ste14p (ICMT) and [3H]-methyl-S-adenosylmethionine (55 µCi/ml,
specific activity 66.8 Ci/mmol) to the reaction mixtures (Hrycyna and others 1995). After
incubating 60 min at 30˚C, the reactions were stopped by the addition of 1M NaOH/1%
SDS, which initiated base hydrolysis of the incorporated [3H]-methyl group. After base
hydrolysis, 50 µl of each mixture was immediately spotted onto a heavy filter paper
lodged into the neck of a scintillation vial containing 10 ml of scintillation fluid (ScintiSafe
Econo 2, Fisher Scientific). After 2-3 hrs the filters were removed, and the radioactivity
released determined by liquid scintillation counting.
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CAAX Proteolysis Reaction on [3H]- farnesylated CSIM Tetrapeptide
Zmpste24 was expressed in insect cells and Ni-purified as described above. The
activity of purified Zmpste24 was reconstituted by diluting the purified Zmpste24 5X into
heat inactivated insect membranes in 50 mM Tris, pH 7.0, and then forming vesicles by
sonication for 3 minutes. CAAX proteolysis mixtures contained, in a total volume of 20 µl,
Ac-*fCSIM-OH (20,000 CPM), 30 µg of either reconstituted Zmpste24 or heat inactivated
membranes, and buffer containing 200 mM NaCl, 200 mM HEPES (pH 7.5), 30 mM zinc
acetate. In the samples preincubated for 15 min at 30oC with 2 mM 1,10
orthophenanthroline (a Zn+2 chelator), zinc acetate was not used in the buffer. After
incubation at 37 ˚C for 20 min, reactions were terminated by the addition of 100 µl of
chloroform-methanol (1:1) followed by 100 µl of 1 M citric acid to achieve phase
separation. The (lower) organic layer was collected, dried under N2, dissolved in ethyl
acetate, and spotted onto plastic TLC plates which were developed in
chloroform:acetone:methanol:acetic acid. (70:15:8:2). Substrate (Rf 0.3) and product (Rf
0.58) were localized by autoradiography and counted using a liquid scintillation counter.
For scintillation counting, the spots were cut and counted in 10 ml of scintillation fluid
(Fisher Scientific).

Cotransfection of Zmpste24 and PrelaminAct into Sf21 Cells
The recipient cells used for cotransfection were Sf21. Eight hours after plating, cells
were infected (baculovirus) with either prelamin Act or both prelamin Act and Zmpste24 in
the presence or absence of lovastatin (10 mg/ml) (Tocris). Sixty-four hours post-infection
cells were collected by scraping and centrifugation at 1,000Xg for 5 min. The cells were
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washed with PBS, resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM
imidazole, pH 8.0), and prelamin Act purified with Ni-NTA beads. The purified products
were analyzed by SDS-PAGE and immunoblot with anti-lamin A or anti-prelamin A.

In vitro Endoprotease assay on [3H]-Mevalonate Labeled PrelaminAct

PrelaminAct purified from insect cells metabolically labeled with [3H]-mevalonate (see
above) was incubated with membranes from insect cells expressing either Zmpste24 or
Erp57 (mock transfected). The reaction mixture was separated on SDS-PAGE (4-12%
MES) and visualized by fluorography. Reactions were also performed with
[3H]-mevalonate labeled prelamin A immobilized on Ni-NTA beads. [3H]-mevalonate
labeled material released was determined at various times by liquid scintillation counting.

In vitro Assay using [35S]-Met labeled PrelaminAct as Substrate

Purified [35S]-Met labeled prelaminAct was incubated with 30 ug of insect membranes
in 50 mM Tris-HCl pH 7.0 in a final volume of 20 ml at 37°C for various periods of time.
Each reaction contained the thiol protease inhibitor E-64 (Roche Molecular Biochemicals)
to reduce background protease activity from the Sf21 insect cells. A
prelaminAct∆CAAX-pBFT4 construct (gift from H.J. Worman; Columbia University) which
contained residues 389-660 (a stop codon after the terminal cysteine) was in vitro
translated in the presence of [35S]-Met with the Quick TnT system from Promega. The
product from this reaction was diluted 400:1 and incubated with membranes as above.
Products were separated on 10% MOPS SDS-PAGE gels then visualized using a
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FUJIFILM FLA-5000 Phosphorimager. Densitometry was performed using the provided
software.

Labeling of Zmpste24 with FFCK
Membranes from Zmpste24 or mock transfected cells were incubated in the presence
of 20 uM FFCK (Immunochemistry Technologies, Bloomington, MN) for 30 min at 37oC.
Where noted, membranes were either first heat inactivated or preincubated in the
presence of TPCK. After incubation, labeled products were purified using Ni-NTA
chromatography and separated on 10% MOPS SDS-PAGE gels. Fluorescence of FFCK
was visualized using a FUJIFILM FLA-5000 Phosphorimager with excitation of 473 nm
and a blue filter. Gels were then transferred to PVDF membranes and western blot
performed with anti-(HIS)6. Western blots were aligned with the fluorescent image with
reference marks. The appropriately labeled 54 kDA bands for FFCK labeled and control
samples were cut out and MALDI-TOF was performed as described above.
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CHAPTER 3
RESULTS

Insect Cell Expressed and Purified Prelamin ACT is Fully Processed
A number of factors were taken into consideration in designing a suitable substrate for
assaying endoproteolytic activity. It is necessary for the substrate to be fully
post-translationally modified at the CAAX motif in order for the prelamin A endoprotease
to cleave the prelamin A substrate (Kilic and others 1997). In addition, because these
assays were to be conducted in vitro, the substrate needed to be soluble. Therefore, the
N-terminal coiled-coiled domain of lamin A was omitted. In light of these considerations, a
C-terminal fragment of prelamin A (residues 389 -664 including the CAAX motif, CSIM)
tagged with (His)6 at the N-terminus, was expressed using a baculovirus expression
system in insect cells and then purified from isolated membranes using Ni-NTA
chromatography. This C-terminal fragment of prelamin A, prelaminAct, has previously
been demonstrated to be water soluble and, therefore, is suitable for in vitro studies
(Barton and Worman 1999). The state of post-translational modification at the CAAX box
of the purified prelaminAct substrate was then monitored using a variety of techniques
(described below).
The purified substrate is recognized in immunoblots by a prelamin A specific antibody
(Fig 7). The prelamin A antibody was raised against the 14 amino acid sequence of
prelamin A (LLGNSSPRTQSPQN), residues 647-660 (Sinensky and others 1994a) which
is removed during endoproteolytic maturation (Figure 1). Immunoblots with an anti-lamin
A specific antibody were also positive (data not shown). The lamin A antibody recognizes
55

a portion of lamin A excluding the prelamin A specific C-terminal 15 residues. These
results indicate that the recombinantly expressed substrate contains both a prelamin A
specific sequence at the C-terminal end and a lamin A specific sequence.

33 kDa

1

2

3

Figure 7 PrelaminAct expressed in insect cells contains carboxy terminal sequence. The
C-terminal half of prelamin A (residues 389-664) fused to (His)6 at the N-terminus was
cloned and expressed in insect cells. The expressed prelaminAct is solubilized from
membranes and purified by binding and elution from Ni-agarose beads as described in
Chapter 2. The elutions were resolved using SDS-PAGE and immunoblot was performed
with anti-prelamin A. Cytosolic fraction (lane 1), membrane fraction (lane 2), and mock
transfected purification (lane 3).

In order to confirm that the prelamin A substrate is prenylated, prelaminAct expressed
in insect cells was metabolically labeled with [3H]-mevalonate, a precursor in the
biosynthetic pathway of isoprenoids. After labeling, the prelaminAct substrate was affinity
purified, separated by SDS-PAGE, and visualized using fluorography (Fig 8). The single
[3H]-labeled band at 33 kDa indicates that the insect cell host is competent for prenylating
the specific CAAX box sequence associated with prelamin A, CSIM.
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33 kDa

Figure 8 PrelaminAct expressed in insect cells contains a prenyl moiety. PrelaminAct was
expressed in insect cells in the presence of 5-R, S-[3H]-mevalonate and purified using
Ni-NTA chromatography. The purified elution was resolved by SDS-PAGE, and
visualized by fluorography.

It is possible for CAAX box proteins to be modified with a geranylgeranyl moiety rather
than a farnesyl. The mevalonate labeling experiment above did not distinguish between
these two potential forms of modification. To verify that the substrate is farnesylated,
prelaminAct was expressed in the presence of [35S]-Methionine. After metabolic labeling,
prelaminAct was separated into membrane associated or cytosolic fractions and then
immunoprecipitated with an anti-farnesyl cysteine specific antibody (Fig 9). The
membrane associated prelaminAct was precipitated by this antibody, consistent with the
conclusion that prelaminAct is properly farnesylated. In contrast, only a small percentage
of the cytosolic fraction of prelaminAct was recognized by this antibody (Fig 9, lanes 3 and
4) consistent with the conclusion that the cytosolically localized protein is not
farnesylated. It has been observed that expression of farnesylated proteins, such as Ras,
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in insect cells results in only a portion of the expressed proteins being lipidated. This is
due to limitations on the capacity of insect cells for isoprenoid biosynthesis (Khosravi-Far
and Der 1995). Therefore, this result is in agreement with the observation that prenylation
targets proteins to membranes. Based on these observations, the membrane fraction
from insect cells expressing prelaminAct was used as the source of prenylated substrate.

33 kDa
1

Beads

2

FT

Membrane

3

Beads

4

FT

Cytosolic

Figure 9 PrelaminAct substrate contains a farnesylated cysteine. Immunoprecipitation of
purified cytosolic and membrane associated [35S]-methionine labeled prelaminAct, with
an anti-farnesyl antibody was performed. Immunoprecipitates (Lanes 1 and 3) and flow
through (FT) (Lanes 2 and 4) of membrane (Lanes 1 and 2) and cytosolic fractions (Lanes
3 and 4) were analyzed by SDS-PAGE and visualized by fluorography.

Finally, to directly demonstrate that the substrate is farnesylated, AAXed and
carboxyl-methylated, MALDI-TOF mass spectrometry on trypsin digested, membrane
associated, prelaminAct isolated as a band from a SDS-PAGE gel, was performed. The
C-terminal farnesylated, AAXed, and carboxyl-methylated peptide, TQSPQNC, (MW
=995.13 Da) was observed (Fig 10). Furthermore, incompletely processed intermediates,
as well as the nascent precursor peaks, were absent from the spectra. These data
confirm that the membrane-bound purified substrate is completely modified with the
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correct post-translational modifications at the CAAX box and, therefore, can be employed
as a valid substrate for assaying the second upstream endoproteolytic conversion in the
processing of prelamin A.

Figure 10 The prelaminAct substrate is fully processed at the CAAX box. MALDI-TOF
analysis on Ni-agarose and SDS-PAGE purified membrane associated prelaminAct was
performed. The 33 kDa band was excised from the gel and digested with trypsin. The
C-terminal peptide (depicted in inset) modified by AAXing, farnesylation, and
carboxyl-methylation (MW 995.13 Da) is observed.
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Zmpste24 Localization in CHO-K1 Cells
Cloning of the full length cDNA for human Zmpste24 was accomplished via RT-PCR
from a HeLa cDNA library. This cDNA for human Zmpste24 was then cloned into the
pCDNA3.1+ construct to verify expression as well as subcellular localization within
mammalian cells. Previous reports have demonstrated that human Zmpste24 is localized
to the ER and the golgi (Kumagai and others 1999). However, unlike yeast Ste24,
Zmpste24 does not contain a canonical c-terminal ER retention motif (Schmidt and others
2000), giving rise to the possibility that Zmpste24 may be found at other locations within
the cell other than the ER. It is to be noted that because Zmpste24 contains 7
transmembrane domains, it is topologically constrained to membranous structures. To
assess the subcellular localization of human Zmpste24 in mammalian cells, Zmpste24
under the control of the constitutive CMV promoter was transfected into CHO-K1 cells
and indirect immunofluorescence was performed. The results (Fig 11) are consistent with
Zmpste24 localization to the ER (reticular staining throughout the cell) and to the nuclear
envelope (perinuclear staining). The nuclear localization of Zmpste24 as well as its
membrane topology are in agreement with data from previous work which demonstrates
that purified nuclear envelope fractions contain endoproteolytic activity (Kilic and others
1999), and that the endoproteolytic conversion of prelamin A to lamin A can be
accomplished solely in the nucleus (Lutz and others 1992).
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Figure 11 Subcellular localization of Zmpste24 expressed in mammalian cells. Zmpste24
was cloned from a HeLa cDNA library into the mammalian expression vector pcDNA3.1
and transiently transfected into CHO-K1 cells. Subcellular localization was determined by
indirect immunofluorescence with anti-Zmpste24 (residues 56-76). Note both the
cytosolic and perinuclear distribution of Zmpste24.

Expression of Zmpste24 in Insect Cells
To produce recombinant enzyme for use in the intended in vitro substrate assays,
human Zmpste24 was N-terminally fused to a (His)6 tag and was expressed in the
baculovirus Sf21 insect system. Zmpste24 was expressed for 72 hours post-infection,
and then purified from detergent solubilized membranes using Ni-bead chromatography.
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Elutions were separated via SDS-PAGE, and then immunoblotted with a Zmpste24
specific antibody (Fig 12). This resulted in a diffuse band with an apparent MW of ~54
kDa, the predicted molecular mass of the protein. From the immunoblot it is evident that
Zmpste24 appears to undergo proteolysis during expression and/or purification. Because
Zmpste24 was purified using Ni-beads, and because the (His)6 tag is located at the
N-terminus, the amino terminus of Zmpste24 is intact. The presence of an intact
N-terminus is further confirmed by immunoblot of the purified material with anti-Zmpste24
(residues 56-76) and anti-(His)6 (Fig 12, lanes 3 and 5, respectively). MALDI-TOF mass
spectral analysis of a tryptic digest of the 54 kDa band indicated sequences in this protein
predicted to be found in Zmpste24 with 34% sequence coverage spanning residues
50-481 (data not shown). This included a sequence corresponding to the predicted
carboxyl-terminal peptide of Zmpste24. A band appearing at 54 kDa in the immunoblot
with anti-Zmpste24 (residues 440-455), is also consistent with the purified Zmpste24
having an intact C-terminus (Fig 12, lane 4). The data obtained from both the western
blots and the mass spectral analysis confirm that full length human Zmpste24 is being
expressed in the insect system.
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Figure 12 Expression of Zmpste24 in insect cells. Zmpste24 was expressed in Sf21 cells
for 72 hours post-infection with high-titer recombinant virus. Cells were lysed using a
microtip sonicator. Total cell lysate was fractionated into membranes which were
solubilized in 1.5% Octylglucoside. Ni-bead chromatography was performed and the 250
mM imidazole elution was separated using SDS-PAGE. Immunoblot with anti-Zmpste24
(residues 56-76) (Lanes 1-3), anti-Zmpste24 (residues 440-455) (Lane 4), or anti-(His)6
(Lane 5) was performed. Lane 1: Ni-agarose purified elution of mock transfected cells.
Lane 2: Total cell extract before purification. Lanes 3-5: Ni-agarose purified elutions of
Zmpste24.

AAXing Activity of Zmpste24 on Yeast a-factor
The above experiments show that the insect system is appropriate for expressing full
length Zmpste24, but these experiments do not show that the enzyme being made is
active. Tam and coworkers have reported that the human enzyme Zmpste24, like its
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yeast homologue Ste24p, possesses endopeptidase activity towards the farnesylated
yeast a-factor CAAX box, resulting in removal of the c-terminal tripeptide adjacent to the
prenylated cysteine, i.e., AAXing (Tam and others 1998). Therefore, to ascertain if insect
cell expressed Zmpste24 is enzymatically active, membranes from insect cells
expressing Zmpste24 were assayed for AAXing activity using farnesylated a-factor as
substrate with the standard base release assay. Briefly, in this assay, removal of the
tripeptide adjacent to the farnesylated cysteine is measured indirectly by the ability of
isoprenylcysteinemethyltransferase (ICMT) to transfer a carboxymethyl group from the
methyl donor S-adenosylmethionine (SAM) to the newly exposed cysteinyl-carboxy group
(Hrycyna and others 1995). Membranes from cells expressing Zmpste24 showed an
approximate 9-fold increase in activity when compared to membranes from mock infected
cells (Fig 13). These results demonstrate that Zmpste24 expressed in insect cells
possesses CAAX endopeptidase activity towards the a-factor substrate. Demonstrating
that the Zmpste24 expressed protein from insect cells contains proteolytic activity against
yeast a-factor is critical to using this system in any further proteolytic studies on prelamin
A.
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Figure 13 AAXing activity of Zmpste24 on a-factor substrate. Membranes derived from
insect cells expressing either human Zmpste24 or Erp57 (Mock) were incubated with the
prenylated a-factor surrogate substrate (gift from Susan Michaelis). Reactions were
performed for 20 min and then stopped by boiling. Recombinant ICMT and the methyl
donor [3H-Methyl]-S-adenosylmethionine were then added to carboxymethylate any
AAXed substrate. Incorporated counts were then released with 1M NaOH and counted.
Reactions were repeated in triplicate.
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AAXing Activity of Zmpste24 on Prelamin A
Although the AAXing activity of human Zmpste24 on the yeast a-factor substrate has
previously been shown in the literature, its ability to AAX prelamin A has not, to this date,
been reported. One of the primary goals of this present body of work is to test the
hypothesis that Zmpste24 is the physiologic AAXing enzyme for prelamin A. To test this
hypothesis, a farnesylated tetrapeptide prelamin A specific CAAX sequence,
Cys-(farnesyl)-Ser-Ile-Met, was tested as a substrate in the base release assay. The
substrate was constructed by synthesis of the tetrapeptide, N-(Ac)-Cys-Ser-Ile-Met, and
then farnesylation of the cysteine using [3H]-farnesyl pyrophosphate (FPP) and purified
farnesyltransferase. This substrate was purified via preparative thin layer
chromatography and then used in a base release assay with Zmpste24 enriched insect
membranes. The data show an approximate 7-fold increase in the activity of membranes
from cells expressing Zmpste24 relative to the activity of membranes from mock infected
cells (Fig 14). Therefore, Zmpste24 has CAAX endopeptidase activity towards the
prelamin A specific CAAX box sequence, N(Ac)-Cys(farnesyl)-Ser-Ile-Met in vitro.
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Figure 14 AAXing activity of Zmpste24 on a prelamin A tetrapeptide. Membranes derived
from insect cells expressing either human Zmpste24 or Erp57 (Mock) were incubated with
the substrate: N(Ac)-Cys(farnesyl)-Ser-Ile-Met. The same procedure was used for base
release as in Fig 8. Reactions were repeated in triplicate.

AAXing Activity of Purified and Membrane Reconstituted Zmpste24
Because the above experiments were conducted on crude membrane preparations,
they do not verify definitively that Zmpste24 is the enzyme directly catalyzing the
proteolytic conversion. To directly verify that this activity is solely based on hydrolysis due
to Zmpste24, the enzyme was purified from detergent solubilized membranes using
Ni-chromatography and reconstituted into heat inactivated insect membranes. The
membrane reconstituted enzyme was tested against the
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N(Ac)-Cys(farnesyl*)-Ser-Ile-Met labeled substrate using a TLC based assay for
measuring the formation of product. This TLC assay has increased sensitivity and
accuracy over the base-release assay used in the previous experiments. Results from
this reconstitution experiment demonstrate that purified Zmpste24 has the ability to AAX
the prelamin A model substrate, farnesylated CSIM (Fig 15). An eight-fold increase in
activity with Zmpste24 infected cells over mock infected is observed as well as the
inhibition of activity upon the addition of Zn+2 chelator 1,10 orthophenanthroline (Opa).
Although the activity does not appear to be inhibited 100%, the level of this activity is not
statistically distinguishable from the level observed in the mock control. Inhibition by Opa
is consistent with the AAXing activity of Zmpste24 being due to a Zn+2 dependent active
site, which is a typical characteristic of metalloproteinases. Also consistent with the
activity being due to a metalloproteinase is the observation that this AAXing activity is not
inhibited by the chymotrypsin like protease inhibitor, TPCK.
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Figure 15 AAXing activity of purified and reconstituted Zmpste24 is Zn+2 sensitive.
Zmpste24 was purified using Ni-agarose chromatography and reconstituted into heat
inactivated insect membranes. N(Ac)-Cys(farnesyl*)-Ser-Ile-Met was incubated with
either mock-infected membranes (lane 1) or reconstituted Zmpste24 preincubated with
no inhibitor (lane 2), 2 mM 1,10-orthophenanthroline (lane 3), or 100 ug/ml TPCK (lane 4).
Products were extracted, separated on TLC, and visualized by fluorography. The
radiolabeled product N(Ac)-S-farnesyl*-L-cysteine was identified by comigration with a
bona fide commercial standard.
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Second Endoproteolytic Processing Activity of Zmpste24
Motivation for these next set of experiments comes from the fact that the experiments
described above confirm that Zmpste24 does indeed possess the first endoproteolytic
AAXing activity towards the substrate prelamin A, but do not answer the question
regarding the role, if any, that Zmpste24 plays in the second endoproteolytic processing
step. In addition to the first processing event, it is also reasonable to hypothesize that
Zmpste24 may catalyze the second endoproteolytic cleavage converting prelamin A to
the mature lamin A. Justification for this reasoning comes from the observation that when
the mouse orthologue to Zmpste24 is knocked out in mice, Zmpste24 -/- cells lose the
ability to process prelamin A to mature lamin A (Bergo and others 2002; Pendas and
others 2002). If the first AAXing reaction is blocked in the processing pathway of prelamin
A to Lamin A, then it follows that the subsequent carboxymethylation and second
endoproteolytic events will not occur (Kilic and others 1997; Bergo and others 2002).
However, if Zmpste24 AAXing activity is abolished, it is feasible that RCE1 may be able to
complement this AAXing defect, as in the case of a-factor in yeast (Boyartchuk and Rine
1998; Tam and others 1998). Therefore, the experimental observations that prelamin A to
Lamin A conversion is blocked in Zmpste24 -/- cells may not be due to the loss in the
AAXing event (due to RCE1 complementation) but may be entirely due to the loss in the
second endoproteolytic reaction. In support of the hypothesis that human Zmpste24 may
have the ability to perform both reactions is the experimental observation that the yeast
orthologue to Zmpste24, Ste24, has the ability to process a-factor at the first and second
proteolytic sites (Tam and others 1998; Tam and others 2001). This leads to the
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hypotheses that Zmpste24 may be performing the first, second, or both endoproteolytic
steps during the processing of mammalian substrate, prelamin A.
In order to test whether Zmpste24 can process prelamin A to lamin A in vivo,
prelaminAct, or both prelaminAct and Zmpste24, was expressed in insect cells, and then
the conversion of prelamin A to lamin A was followed via immunoblot. Coexpression of
Zmpste24 and prelamin A results in a product, 2 kDa smaller in MW then prelaminAct,
that is recognized by a lamin A antibody, indicating that conversion of prelamin A to lamin
A is being mediated by Zmpste24 expression (Fig 16). This conversion to lamin A is
blocked by incubation of the cells with lovastatin, an inhibitor of isoprenoid biosynthesis,
which previously has been demonstrated to block prelamin A maturation in mammalian
cells by blocking prenylation (Beck and others 1990; Sinensky and others 1990). It was
observed that the prelamin A antibody recognizes the putative 33 kDa prelaminAct
product only (data not shown), while the lamin A antibody recognizes both the
unprocessed form of prelaminAct (upper band) and the processed form, lamin A (lower
band). This result demonstrates that the change in migration is due to a cleavage that
removes the C-terminal prelamin A sequence.
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Figure 16 Zmpste24 processing of prelaminAct in vivo. Zmpste24 was virally transfected
into insect cells expressing N-terminally (His)6 tagged prelaminAct or prelaminAct
mutated at the endoproteolytic cleavage site (L647 Æ R). The cells were then incubated for
72h in the presence or absence of lovastatin. PrelaminAct and laminAct were purified
using Ni-agarose chromatography, separated by SDS-PAGE and visualized by
immunoblot with anti-lamin A.

To determine the specific cleavage site at the C-terminus of prelamin A, this
coexpression experiment was repeated with a prelaminAct construct containing the
hexapeptide sequence RSY-RLG bearing a point mutation (L647ÆR) at the p1 site of the
wild type sequence RSY LLG. Other in vivo experiments have shown that this mutation of
prelamin A cannot be processed to lamin A when expressed in mammalian cells
(Hennekes and Nigg 1994). Zmpste24 coexpression along with this uncleavable mutant
of prelaminAct resulted in no conversion, as expected (Fig 16, lane 5). This in vivo data
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supports the conclusion that Zmpste24 is hydrolyzing the peptide bond of prelamin A
between Tyrosine646 and Leucine647, as would be expected for the bona fide prelamin A
endoprotease. The overall results of these in vivo experiments along with the observed
substrate specificity is particularly indicative that processing is governed by the
expression of Zmpste24, considering the absence of lamin A in insect cells, and,
therefore, the probable absence of similar endogenous protease activities.
It is important to point out at this point that attempts to purify Zmpste24 and
reconstitute the second endoproteolytic activity were not successful. The results from
these trials suggested that Zmpste24 loses this second activity upon extraction from the
membranes. Various detergents were used to carry out membrane extraction and
solubilization of the enzyme including octylglucoside, NP-40, TX-100, and deoxycholate.
From these trials, octylglucoside performed the best in extraction and in further
downstream purification steps (Ni-chromatography). Various aliquots along the entire
process of extraction, purification, and reconstitution, process were tested for activity. The
only fractions that possessed any type of activity associated with the second
endoproteolytic step were membranes before extraction. Reconstitution was attempted
on the purified Zmpste24 fractions by mixing with membrane extracted lipids from either
insect cells, HeLa cells, or E.coli cells and dialyzing against various reconstitution buffers
overnight to form vesicles. These reconstituted vesicles all gave negative results when
tested for endoproteolytic activity. Although the first AAXing endoproteolytic activity was
able to be reconstituted with ease, the second activity was only evident from Zmpste24
enriched membranes before any further processing steps. One possible explanation for
this loss of activity is that some other membrane associated co-factor is needed for the
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second endoproteolytic activity. The significance of these observations will be discussed
in detail within Chapter 5 - Discussion. For these reasons, all further experiments
demonstrating the second endoproteolytic activity of Zmpste24 on prelamin A are
conducted on Zmpste24 enriched membranes produced from insect cells.
The above in vivo experiments provide a physiological framework for the role of
Zmpste24 in the processing of prelamin A, but do not definitively demonstrate that this
proteolytic activity is uniquely due to Zmpste24 mediated catalysis. To determine if the
second prelamin A endoproteolytic cleavage can be reconstituted in vitro, a prelaminAct
substrate was constructed which was metabolically labeled with [3H]-mevalonate, a
biosynthetic precursor in the isoprenoid pathway. A substrate bearing a radiolabeled
farnesyl moiety allowed the endoproteolytic reaction to be followed simply by measuring
the counts associated with the ~2 kDa C-terminal farnesylated fragment. When incubated
in vitro with Zmpste24 enriched membranes, this substrate released a ~ 2 kDa

[3H]-labeled fragment, the approximate size of the last 15 residues of prelamin A, as the
sole labeled product (Fig 17). The negative control, mock control membranes, showed no
apparent activity towards this substrate.
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Figure 17 Zmpste24 catalyzed cleavage of a 2 kDa fragment from prelaminAct.
PrelaminAct was metabolically labeled with [3H]-mevalonate for 16 hours, 48 hours after
infecting with the prelaminAct construct. PrelaminAct was then purified with Ni-agarose.
Products formed after incubation with either mock transfected (lane 1) or Zmpste24
transfected (lane 2) membranes were separated by SDS-PAGE and visualized by
fluorography.

To evaluate the kinetics of the release of this 2 kDa prenylated fragment, an assay
was designed in which the [3H]-mevalonate labeled prelaminAct substrate was bound to
Ni-agarose beads. The bound and labeled prelaminAct was washed extensively but was
not eluted from the beads. The immobilized prelaminAct then served as the substrate in
the kinetic assays. After incubating the immobilized prelaminAct with Zmpste24
membranes, the tritium counts in the supernatant were monitored at various time points.
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From analysis of the gel fluorogram (Fig 17), it is evident that the major product after
incubation with Zmpste24 membranes is a ~2 kDa fragment. Therefore, measuring any
releasable counts from prelaminAct immobilized to beads upon incubation with Zmpste24
enriched membranes can be safely interpreted as this 2 kDa product. The results of this
kinetic bead assay show the that the formation of product increases with time and goes to
completion between 1 and 2 hours (Fig 18). Notably, membranes from mock infected
cells did not give rise to measurable product, consistent with the conclusion that product
formation arises from the expressed Zmpste24 rather than an endogenous activity of the
insect cell membranes.
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Figure 18 Kinetics of release of ~2 kDa product from prelaminAct. Purified
[3H]-mevalonate labeled prelaminAct was immobilized on Ni-agarose beads and washed
extensively. The beads were incubated with membranes from Zmpste24 or mock
transfected cells, or just buffer. At various times, aliquots of the supernatant were counted
to determine release of the farnesylated C-terminus of prelamin A (-♦- = Zmpste24
membranes, -■- = mock infected membranes, -▲- = blank control (just buffer)).

The results from the above two experiments definitively show that a ~2 kDa
prenylated C-terminal fragment of prelaminAct is being released upon incubation with
Zmpste24 enriched membranes. To complement these results and to determine if this
cleavage reflects the physiological processing pathway of prelamin A, it was important to
establish whether or not the parent 33 kDa substrate was being converted to a 31 kDa
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product. To accomplish this, it was necessary to design a substrate whose N-terminally
released product could be followed as a readout of the processing event. This was carried
out by expressing and purifying a [35S]-Met metabolically labeled 33 kDa prelaminAct,
and then monitored the processing of this substrate upon incubation with membranes
from cells expressing Zmpste24. The results reveal that the 33 kDa prelaminAct band
was converted to a 31 kDa form in a time-dependent fashion (Fig 19A). In the controls
with membranes from mock transfected cells incubated with wild type prelaminAct
substrate, we observed little or no conversion of the parent prelaminAct substrate (Fig
19B). However, a non-specific proteolytic activity degraded the 31 kDa formed product
over time, which is evident from inspection of the lower band (Fig 19A). It was determined
through trial and error that preincubation of membranes with the thiol protease inhibitor
E-64 reduced this non-specific background degradation of prelamin A and allowed the
measurement of enriched Zmpste24 activity but did not completely eliminate this
background degradation of the formed product. This degradation could be due to any
number of non-specific carboxy, amino, or endopeptidases which are endogenously
expressed in the Sf21 cell line. It is important to note that the only way to eliminate any
endogenous proteolytic background is to purify and reconstitute the activity of Zmpste24,
which was attempted but was unsuccessful. Incubating the membranes with any type of
protease inhibitors in an attempt to eliminate this background could potentially eliminate
the activity of Zmpste24 and, therefore, would be unfruitful. The protease inhibitor E-64 is
a viable means to reduce some of this background because it is specifically designed to
inhibit thiol proteases. Nonetheless, these results show that membranes from Zmpste24
expressing cells have the ability to convert prelaminAct in a time dependent fashion to a
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form that is approximately 2 kDa lower in MW, consistent with the characteristics
associated with the prelamin A endoprotease. These results also demonstrate that the
overall design of the assay for monitoring this type of activity is robust and sensitive.
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Figure 19 Zmpste24 can endoproteolytically process prelaminAct to laminAct.
PrelaminAct was metabolically labeled with [35S]-methionine in insect cells and purified
with Ni-agarose. The purified substrate was incubated with either Zmpste24 or mock
transfected membranes in the presence of E-64 for various times. The products were
separated by SDS-PAGE, the gels were dried, and visualization by phoshorimager
analysis was performed. A) PrelaminAct incubated with membranes derived from
Zmpste24 expressing insect cells. B) PrelaminAct incubated with membranes derived
from Erp57 expressing insect cells (mock).

The results presented in the figure above do not conclusively demonstrate the site of
cleavage. To demonstrate the site of cleavage, a [35S]-Met metabolically labeled 33 kDa
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prelaminAct bearing a point mutation at the p1 site of cleavage (L647ÆR) was expressed
and purified. This mutation, as shown in the results of the in vivo experiments (Fig 16), is
unable to be converted to fully mature laminAct. Using this uncleavable mutant with this
endoproteolytic assay resulted in little or no conversion when compared to the processing
of wild type prelaminAct (Fig 20). The extent to which endoproteolytic conversion
occurred was quantified by densitometry and expressed as % conversion to the 31 kDa
form. It is clear that the expression of Zmpste24 is resulting in proteolytic activity that is
consistent with the expected substrate specificity of the prelamin A endoprotease.
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Figure 20 Zmpste24 can process prelaminAct at the sequence RSY-LLG. PrelaminAct or
its RSY-RLG (L647 ÆR) mutant were metabolically labeled with [35S]-methionine in insect
cells and purified with Ni-agarose. The labeled substrates were incubated with Zmpste24
membranes for various times. The products were separated by SDS-PAGE and analyzed
by phosphorimager analysis and quantitative densitometry. From the densitometry of the
parent 33 kDA band and the lower 31 kDA band, the relative formation of the 31 kDa
product ([31 kDa Counts]/ [33 kDa + 31 kDa Counts]) was calculated as a function of time.
(-■- = Zmpste24 membranes with WT prelaminAct, -▲- = Zmpste24 membranes with
RSY-RLG mutant prelaminAct)
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The 33 kDa band is recognized by prelamin A antibody, while both the 33 kDa and 31
kDa bands are recognized by the lamin A antibody (data independently verified on
unlabeled substrate and not shown). Confirmation of the identify of these two bands by
mass spectral analysis revealed that the 31 kDa band is missing the C-terminal peak
corresponding to the peptide SYLLGNSSPR (MW 1094.21 Da). This is consistent with
the conclusion that Zmpste24 cleaves between Tyrosine646 and Lysine647, as would be
the case for lamin A maturation in whole mammalian cells (Fig 21).
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Figure 21 Mass spectral identification of prelaminAct to laminAct conversion. Zmpste24
membranes were incubated with the purified prelaminAct substrate and the reaction was
repurified using Ni-agarose beads. The beads were boiled and run on SDS-PAGE to
separate the 33 kDa parent substrate from the 31 kDA product. Each band was excised
and tryptic digested. MALDI-TOF analysis of the tryptic digested 33 kDa (top spectrum)
and 31 kDa (bottom spectra) gel excised bands was performed. Notice the
disappearance of the peak corresponding to the peptide SYLLGNSSPR (MW 1094.21
Da) in the 31 kDa band. The peak appearing at 920.06 corresponds to the predicted
peptide from the prelaminAct sequence between residues 428-435.
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Endoproteolytic Processing of PrelaminAct Depends on Processing at the CAAX Box
As mentioned earlier, the membrane bound substrate is fully processed in that it is
farnesylated, AAXed, and carboxyl-methylated. Previous studies assaying the activity of
nuclear envelope fractions on a model peptide substrate have shown that it is necessary
for prelamin A to be fully processed at the CAAX box before it can act as a substrate for
the endoprotease (Kilic and others 1997). In order to evaluate if the dependence on
processing of prelamin A by Zmpste24 is contingent upon full processing at the CAAX
box, an in vitro translated [35S]-Met labeled prelaminAct construct containing a stop codon
after the cysteine, designated prelaminAct ∆AAX, was expressed (Barton and Worman
1999). Due to the lack of the tripeptide adjacent to the CAAX box cysteine residue (i.e.,
the AAX sequence), this substrate contains a cysteine at the carboxyl terminus that is
neither farnesylated or carboxymethylated. In the absence of a farnesylated and
carboxyl-methylated cysteine, prelaminAct substrate is not cleaved by Zmpste24 to any
measurable extent (Fig 22). Comparing this to the results when a fully processed
substrate was used (Fig 19A), leads to the conclusion that cleavage of prelamin A to
lamin A by the endoprotease is, indeed, dependent upon a cysteine residue that is
prenylated and carboxymethylated. Although this experiment did not distinguish between
the enzyme-substrate specificity of a prenylated non-carboxymethylated substrate or a
carboxymethylated non-prenylated substrate, it does, nonetheless, show that a non
modified cysteine residue confers a lack of substrate processing. This also corroborates
the findings of the cotransfection experiment which demonstrated that lovastatin
treatment abolishes conversion of prelamin A to lamin A (Fig 16). Taken together, these
results demonstrate the specific cleavage of prelaminAct in vitro by Zmpste24, and that
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Zmpste24 behaves in a consistent manner to what is already known regarding the
specificity and nature of the prelamin A endoprotease.
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Figure 22 Endoproteolytic processing of prelamin A depends on CAAX box. A
prelaminAct ∆AAX construct in the pBFT4 vector was in vitro translated using a rabbit
reticulocyte transcription/translation system in the presence of [35S]-Met. This substrate
was incubated with Zmpste24 membranes for up to 4 hours. The products of this reaction
were resolved with SDS-PAGE and imaged with a phosphorimager.

The Catalytic Mechanism Responsible for the Second Endoproteolytic Conversion
The above experiments demonstrated conclusively that Zmpste24 has the ability to
mediate both endoproteolytic events involved in the maturation pathway of lamin A. From
what is presently known about Zmpste24, it is apparent that this protein contains the
highly conserved Zn+2 dependent metalloprotease motif HEXXH and, that AAXing activity
associated with Zmpste24 is Zn+2 dependent (Schmidt and others 2000). However, prior
in vitro studies from our laboratory are not consistent with the second endoproteolytic

activity being due to a metalloprotease. Rather, these studies, performed with various
protease inhibitors, were consistent with the prelamin A endoprotease being a
chymotrypsin like enzyme with a serine active site (Kilic and others 1999). In order to
address this apparent discrepancy, the effect of various protease inhibitors on Zmpste24
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catalyzed conversion of prelaminAct to laminAct was investigated using the same type of
assay used in Fig 19. Zmpste24 enriched membranes were preincubated with various
protease inhibitors, and substrate conversion reactions were performed in triplicate for 90
minutes. After phoshorimager analysis, the % conversion from 33 kDa to 31 kDa was
quantitated. The results indicate that the conversion of prelamin A to lamin A is blocked by
the serine protease inhibitors AEBSF and N-tosyl-L-phenylalanine chloromethyl ketone
(TPCK) but is not inhibited to any appreciable extent with a mixture of Zn+2 chelators
EDTA and 1,10-orthophenanthroline (Fig 23). Given the specificities of TPCK and
AEBSF, these results suggest that the endoproteolysis of prelamin A by Zmpste24 is
mediated by a chymotrypsin-like active site and not a Zn+2 dependent site.
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Figure 23 Zmpste24 endoproteolysis of prelamin A is sensitive to chymotrypsin inhibitors.
Endoproteolysis reactions on [35S]-methionine prelaminAct were performed as in Fig 14
for 90 minutes in the presence or absence of various serine and zinc metalloprotease
inhibitors (1,10 orthophenanthroline 2 mM, EDTA 10 mM, AEBSF 1mg/ml, TPCK 100
ug/ml, FFCK 20 uM). Reactions were performed in triplicate and the relative formation of
the 31 kDa product (% of total prelaminAct) was quantified at 90 minutes using
densitometry.

In order to confirm that a chymotrypsin-like active site exists within Zmpste24, we
attempted to affinity tag the putative active site histidine with FFCK
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(5(6)-carboxyfluoresceinyl-L-phenylalanine chloromethyl ketone), a fluorescent analogue
of TPCK (Grabarek and others 2002a; Grabarek and others 2002b). FFCK specifically
inhibits chymotrypsin-like proteases by the same mechanism as TPCK, namely by
alkylation of the active-site histidine (Ong and others 1965; Shaw and Ruscica 1971). In
this manner, both FFCK and TPCK affinity label active sites that function by a
chymotrypsin like catalytic mechanism. Our results show that FFCK, like TPCK, was able
to inhibit Zmpste24 endoprotease activity in vitro (Fig 23). To confirm that FFCK is directly
interacting with Zmpste24, membranes from insect cells expressing Zmpste24, were
incubated with FFCK followed by purification of Zmpste24 using nickel-affinity
chromatography. The eluted fractions containing Zmpste24 were resolved by
SDS-PAGE, and the fluorescent protein visualized (Fig 24). The fluorescently labeled
purified protein runs at approximately 54 kDA and comigrates with Zmpste24 visualized
by western blot with anti-(His)6. Preincubation of Zmpste24 with TPCK blocks
incorporation of FFCK, confirming that FFCK and TPCK inhibit Zmpste24 by a similar
mechanism, presumably alkylation of the active site histidine.
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Figure 24 Labeling of Zmpste24 with FFCK. Membranes from insect cells expressing
(His)6-Zmpste24 were incubated with the fluorescently labeled TPCK analogue, FFCK.
After incubation with FFCK, Zmpste24 was purified using Ni-agarose chromatography
and resolved by SDS-PAGE. Fluorescent imaging was performed using an excitation of
475 nm with a blue filter on a FUJIFILM-FLA 5000. Lane 1: Zmpste24 membranes
incubated with FFCK. Lane 2: Zmpste24 membranes with no FFCK. Lane 3: Mock
membranes incubated with FFCK. Lane 4: Zmpste24 membranes preincubated with
TPCK before incubation with FFCK. After imaging, the proteins on this gel were
transferred to a PVDF membrane and the identity of the labeled band confirmed by
immunoblotting with anti-(His)6 and alignment of the images using predefined reference
points.

To confirm that the FFCK labeled Zmpste24, both the FFCK labeled and non-labeled
Zmpste24 bands were isolated and subjected to tryptic digestion followed by MALDI-TOF
mass spectral analysis. All peaks identified in the MALDI-TOF analysis mass
fingerprinted the band as Zmpste24, with approximate 47% sequence coverage. No
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peaks were obvious in the spectra that would represent the theoretical shift in MW upon
FFCK derivitization (MW = 557 Da). Such a peak may not fly in the MALDI-TOF machine
or may block tryptic digestion of a nearby tryptic cleavage site. The negative result
obtained from the mock membrane control (Fig 24, lane 3), in addition with the
immunoblot and mass spectral analysis, lead to the conclusion that FFCK is able to
affinity tag Zmpste24.
As a final demonstration that the second endoproteolytic activity of Zmpste24 is not
due to the Zn+2 dependent catalytic mechanism, the conserved HEXXH motif in
Zmpste24 was deleted using site directed mutagenesis. In yeast, deletion of the HEXXH
domain of Ste24 completely abolishes the proteolytic processing of a-factor. This
∆HEXXH mutant was constructed and expressed in the insect cell system. This mutant

was compared to WT Zmpste24 for its ability to perform the first and second
endoproteolytic reaction. The results from this experiment show that deleting the HEXXH
motif in Zmpste24 abolishes its ability to AAX a-factor (Fig 25A). However, the ability of
the ∆HEXXH mutant of Zmpste24 to endoproteolytically process prelaminAct to laminAct
is retained and is comparable to the activity observed for WT Zmpste24 (Fig 25B). The
results from this experiment were identical to the results obtained from assaying a His335
ÆAla mutation of Zmpste24 (data not shown). This particular point mutation abolishes the

critical zinc coordinating histidine in the HEXXH motif, resulting in a motif containing
AEXXH. This control is significant for it shows that the loss of AAXing activity is due to a
loss of the catalytic mechanism associated with the Zn+2 coordinating Histidine and is not
due to an overall gross steric change induced by deleting the HEXXH motif entirely. This
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result clearly demonstrates that the AAXing hydrolysis and second endoproteolytic
reaction on prelaminAct are not mediated by the same catalytic mechanism.
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Figure 25 Deletion of HEXXH motif abolishes AAXing, not endoproteolysis. A HEXXH
deletion mutant of Zmpste24 was expressed in insect cells. Membranes from these insect
cells were used in either a A) Base release AAXing assay on a-factor (as in Fig 13) or B)
Endoproteolysis reaction on [35S]-Met labeled prelaminAct (as in Fig 19). In each
experiment, a WT Zmpste24 control was used for comparison.
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Attempts to Locate Second Active Site within Zmpste24
The data obtained from the protease inhibition profiles, affinity labeling by the
chymotrypsin inhibitor, FFCK, and the HEXXH deletion mutant all lead to the same
conclusion: The second endoproteolytic reaction is being catalyzed by an active site
different from the canonical HEXXH zinc metalloproteinase motif. Presumably, this active
site would be homologous to the endoproteinase sites contained in the serine family and
, more particularly, to the chymotrypsin family s1. In this family of proteases, a catalytic
triad (His, Asp, Ser) forms a charge relay system to catalyze the hydrolysis of the amide
peptide linkage (Barrett and Rawlings 1995). The most obvious experiment to conduct to
determine if Zmpste24 contains such an active site is in silico through use of the various
bioinformatic tools available through the NCBI and the EMBL-EBI. A number of blast
algorithms were performed on Zmpste24 against the non-redundant protein databases at
these websites, and the results showed that Zmpste24 has no significant homology to any
of the known protease families, other than the metalloproteinase family, M48. To increase
the sensitivity of these blast algorithms to find distant homology matches that are not
detected in a first attempt, the PSI (Position Specific Iterative) blast algorithm was used
with 4 iterations. In this repetitive algorithm, a Position Sensitive Scoring Matrix is
obtained (PSSM) for each iteration that tabulates in a matrix form the amino acid
substitution frequencies each individual residue along the protein. This PSSM matrix that
is formed on each iteration is then used in the next iteration of a RPS (Reverse Position
Specific) blast algorithm. On each iteration, new proteins are identified with remote
homology to the query sequence and continues until the algorithm converges (no new
members are identified in any additional iterations). The results of this analysis of
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Zmpste24 were also negative in that they did not detect any homologous protein family
members within the serine protease family across all databases organisms.
In the course of the blast attempts at discovering a second serine like active site, it
became apparent that there is an insertional sequence in human Zmpste24 when
compared to orthologues in lower organisms (such as yeast) between residues 290 and
327. This insertional sequence, as predicted through topology modeling, is most likely
within a cytosolic loop between transmembrane segments 5 and 6 (the same loop that
bears the HEXXH motif). Within this loop is the tripepeptide DSG, which is a conserved
sequence in the active sites of many serine proteases. A ClustalW alignment is shown for
this region of Zmpste24 alongside the corresponding regions surrounding the serine
active residue of representative serine family proteases (Fig 26). This putative serine site
was attractive because it was in a region missing from yeast and other lower organisms,
which presumably do not convert prelamin A to lamin A as in the mammalian cell.
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gi|4506145|TrypsinI-Human
gi|6678439|TrypsinII-Mouse
gi|105619|Chymotrypsin-Human
gi|13374559|Chymotrypsin-Mouse
gi|135020|Subtilisin-Bacillus
gi|15529992|ElastaseI-Human
gi|33239381|ElastaseI-Mouse
gi|20384644|Zmpste24-Mouse
gi|18379366|Zmpste24-Human

DS CQ GD S G GP VV
DS CQ GD S G GP VV
S S CMGD S G GP L V
S S CQ GD S G GP L V
T S L N GT S MAS P H
S G CQ GD S G GP L H
S G CQ GD S G GP L H
KD NQ E E S G ME AR
KD I Q E D S G ME P R

Figure 26 Alignment of putative serine site in Zmpste24 with other serine like enzymes.
Human and mouse Zmpste24 were aligned in a 12 amino acid stretch surrounding the
putative serine active site with other representative members of the serine protease
family (ClustalW algorithm). Black background represents an identical match, light gray
represents a similar substitution.

Therefore, our first attempt at identifying the serine active site was to mutate this serine to
an alanine (Ser298 Æ Ala), and to assay this for endoproteolytic activity. However, when
the second endoproteolytic activity of this mutant was compared to wild type against the
[35S]-Met labeled prelaminAct substrate, the activities were virtually identical (data not
shown).

Analysis of Zmpste24 C-Terminal Truncations
Because there are 33 other serine residues within Zmpste24, it was not efficient to
mutate each one in the insect based system that was being used for the WT studies. To
narrow down a region that may contain the active site, or a residue associated with the
active site, 4 serial C-terminal truncations of Zmpste24 were constructed. This was
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accomplished by site directed mutagenesis of the wild type construct to introduce
premature stop codons at predetermined locations. The placement of the stop codons
was chosen strategically within predicted cytosolic or lumenal loop regions outside the
boundaries of transmembrane regions (Fig 27). Placement of the stop codons in these
regions allowed for proper transmembrane insertion of predicted transmembrane helices
n-terminal to the stop codon.

C109

P230

Y379

L290

HEXXH

Figure 27 Placement of stop codons used in generation of Zmpste24 truncations. Shown
is a predicted transmembrane topology map for Zmpste24, as predicted by the TMHMM
Server v. 2.0 server (http://www.cbs.dtu.dk/services/TMHMM/). The positioning of the 4
amino acids mutated into stop codons (C109, P230, L290, and Y379) are shown.
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The Y379Stop mutant was chosen because a similar truncation is observed in
patients who have mandibuloacral dysplasia (MAD) or restrictive dermopathy (Agarwal
and others 2003; Navarro and others 2004; Navarro and others 2005). This premature
truncation in these patients occurs from a Phe361fsX379 mutation, which is a frameshift
introduced from a spurious thymidine in the DNA ORF causing a premature stop to occur
at residue 379 (Agarwal and others 2003). We wanted to assay this mutant for both
AAXing and endoproteolytic activity to correlate the disease phenotype with a defective
step in prelamin A processing, if any. Our results from this study indicate that a premature
truncation of Zmpste24 introduced at residue 379 results in loss of AAXing activity with
retention of the second proteolytic activity (Fig 28). This AAXing result correlates with the
results found by Agarwal and others, who determined that the Phe361fsX379 mutant
form of Zmpste24 could not complement a Ste24 deletion mutant of yeast defective in
processing of the prenylated yeast substrate, a-factor (Agarwal and others 2003). The
results of the endoproteolytic assay on prelaminAct are novel and demonstrate that the
phenotype seen in MAD and RD patients is more than likely due to an inability of
Zmpste24 to AAX the prelamin A substrate. Also worthwhile noting is the fact that the
HEXXH motif (residues 335-339) is retained in this truncated form of Zmpste24, indicating
that some other sequence C-terminal to the HEXXH motif is needed for AAXing to occur.
Most likely, this is a putative upstream glutamate residue (Such as Glu402) needed to
coordinate the Zn+2 ion, a typical feature found in the zincin family of zinc
metalloproteinases (Hooper 1994). Another explanation could be that residues
C-terminal to Y379 are needed for substrate recognition and/or proper folding of
Zmpste24.
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Figure 28 Y379Stop truncation of Zmpste24 abolishes AAXing, not endoproteolysis. A
Y379Stop mutant of Zmpste24 (resembling the Zmpste24 mutation found in MAD) was
expressed in insect cells. Membranes from these insect cells were used in either A) base
release AAXing assay on a-factor (as in Fig 13) or B) Endoproteolysis reaction on
[35S]-Met labeled prelaminAct (as in Fig 19). In each experiment, a WT Zmpste24 control
was used for comparison.
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The overall results obtained from assaying the activity of the Zmpste24 truncations on the
[35S]–Met labeled prelaminAct substrate showed that complete loss of endoproteolytic
activity occurred for the C109Stop construct (Fig 29). From this data it can not be
assumed that an active site serine residue is between residues 109 and 230. This is
because a number of different explanations could explain this data, including: loss of one
or all of the active site residues in the catalytic triad (His, Ser, or Asp); loss of substrate
recognition; improper folding or topology of Zmpste24; or any combination of these
factors.
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%Conversion (33 kDa to 31 kDa) XXX
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Figure 29 Effect of C-terminal truncations of Zmpste24 on processing of prelamin A.
Endoproteolysis reactions on [35S]-methionine prelaminAct were performed as in Fig 19
for 45 minutes in the presence of membranes from cells expressing WT, Y379Stop,
L290Stop, P230Stop, and C109Stop forms of Zmpste24. The relative formation of the 31
kDa product (% of total prelaminAct) was quantified at 45 minutes using densitometry.
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CHAPTER 4
DISCUSSION

The body of this work has explored the role that Zmpste24 plays in the processing
pathway of the nuclear envelope scaffolding protein, prelamin A. Among the milieu of
post-translationally modified mammalian proteins, prelamin A is distinctive in that it
undergoes two distinct prenylation dependent endoproteolytic clips at the carboxy
terminus. In the past, the exact identity of the enzyme responsible for the first AAXing
reaction as well as the prelamin A endoprotease have remained elusive, but recent
biological data moved Zmpste24 to the forefront of likely candidates. Such evidence
includes the observation that Zmpste24 -/- mice fail to process prelamin A to lamin A and
present phenotypical defects associated with lamin A mutations (Leung and others 2001;
Bergo and others 2002; Pendas and others 2002). Even more recently, it has been shown
in humans that Zmpste24 is prematurely truncated in patients with restrictive dermopathy
( Navarro and others 2004; Navarro and others 2005), mandibuloacral dysplasia (Agarwal
and others 2003), and HGPS (Shackleton and others 2005), pathologies that are also
caused by mutations in the LMNA gene. This genetic data in conjunction with the
knowledge of the parallel processing pathways of a-factor in yeast and lamin A in
mammals, generated the obvious hypothesis that Zmpste24 is involved in the proteolytic
maturation of prelamin A. It was the goal of this current research to validate this in vivo
data by assaying the function of Zmpste24 in vitro with respect to the substrate prelamin
A.
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Because of the exotic set of post-translational modifications made in the processing
pathway of prelamin A and the direct link between these modifications and the two
proteolytic processing steps, it was necessary to carefully design and construct
substrates that mimic the physiologic processing events of prelamin A. Each
endoproteolytic reaction occurs on substrates with unique molecular constraints,
necessitating the design and construction of two different model substrates for monitoring
each processing event. To follow the AAXing reaction, a tetrapeptide substrate mimicking
the farnesylated CAAX box of prelamin A was synthesized, a straightforward biochemical
method. However, designing a substrate for assaying the second endoproteolytic activity
was more complicated in that it required a substantial portion of the c-terminus of the
prelamin A molecule and needed to possess a farnesylated and carboxymethylated
carboxyl terminal cysteine. The insect cell line was chosen to express a 33 kDa soluble
form of the c-terminus of prelamin A (prelaminAct) because of its known fidelity in
faithfully reproducing post-translational modifications that typically occur in the
mammalian cell. Indeed, this substrate was confirmed to possess a fully processed
cysteine bearing a farnesyl moiety and carboxymethyl group through mass spectral
analysis (Fig 10).
The results presented in the body of this work have shown that membranes derived
from Zmpste24 expressing insect cells have the ability to process prelamin A model
substrates at two steps in the endoproteolytic pathway, namely AAXing (Fig 14) and
c-terminal endoproteolysis (Fig’s 17-19). Such a dual function for this human enzyme is of
no surprise because the yeast form of this enzyme is also able to process the a-factor
substrate in a similar fashion at two points along its maturation pathway
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(Fujimura-Kamada and others 1997; Tam and others 1998; Schmidt and others 2000;
Tam and others 2001). More specifically, a-factor is processed in a parallel manner to
prelamin A with respect to the first set of four post-translational modifications made at the
c-terminus, namely farnesylation, AAXing, carboxymethylation, and endoproteolysis, and
then diverges from the prelamin A pathway by undergoing a third endoproteolyis reaction
(Anderegg and others 1988; Chen and others 1997). During a-factor maturation, yeast
Ste24 is responsible for both the AAXing reaction and the first endoproteolytic hydrolysis
26 residues upstream from the prenylated cysteine between threonine and alanine. Tam
and others and Schmidt and others have discovered that human Zmpste24, like yeast
Ste24, is able to endoproteolyze a-factor at these same locations in vivo and in vitro (Tam
and others 1998; Schmidt and others 2000). Such an observation is strictly artificial in
nature, because a-factor biogenesis does not occur in humans. However, extrapolating
this yeast data to the realm of the mammalian cell does bring to light the type of structural
moieties and constraints that may be present in the surrogate mammalian substrate. It is
of interest that a singular protease can perform two separate cleavages using two
different substrate recognition specificities, namely one being a prenylated CAAX box,
and the other being upstream from this prenylated cysteine. The distance between the
two cleavage sites is not a conserved parameter when comparing the yeast and human
forms of Zmpste24 (yeast cutting 26 and human cutting 15 residues upstream from this
prenylated cysteine).
Along these lines, the results reported in this body of work elucidate the identity of the
bona fide physiological substrate for Zmpste24 by showing that this protease is capable
of both AAXing (removal of the tripeptide adjacent to the prenylated cysteine) and
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endoproteolysis of prelamin A 15 amino acids upstream from this prenylated cysteine
between tyrosine646 and leucine647. The cleavage site was identified by assaying a
noncleavable prelaminAct point mutant (Leu647Æ Arg) and by mass spectral analysis of
the 31 kDa formed product (Fig’s 20 and 21). Even though the conserved hexapeptide
region surrounding the cut site of prelamin A is not identical to the region surrounding the
cut site of a-factor (prelamin A: RSY LLG; a-factor: TAT AAP), an enzymatic similarity
between human Zmpste24 and yeast Ste24 is to be expected, considering that they are
36% identical and 51% similar in sequence homology, share a 7 transmembrane
topology, and contain a HEXXH active site (Tam and others 1998).
The in vitro data provided in this body of work show that Zmpste24 is capable of
performing both endoproteolytic steps in the maturation of prelamin A. However, these
data do not rule out the possibility that other enzymes in the cell may be able to carry out
either AAXing or endoproteolysis in addition to Zmpste24. However, both endoproteolytic
steps can not have more than one enzyme responsible for its catalysis. This limitation
comes from the observation that Zmpste24 loss of function mutants fail to convert
prelamin A to lamin A at the second endoproteolytic cut site, although the extent of
processing of the CAAX box of prelamin A has not been experimentally determined in
vivo. If Zmpste24 as well as another protease were responsible for performing both

AAXing and endoproteolysis, then a Zmpste24 loss of function mutation would not cause
an accumulation of a lamin A precursor because the enzyme with overlapping
functionality would complement the deficiency due to Zmpste24. Therefore, the fact that
prelamin A accumulates when Zmpste24 is knocked out argues that Zmpste24 is the sole
enzyme mediating either the first or second endoproteolytic steps. In yeast, two distinct
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enzymes are responsible and redundant for AAXing a-factor; RCE1 and Ste24
(Boyartchuk and others 1997; Boyartchuk and Rine 1998; Tam and others 1998). When
both RCE1 and Ste24 are deficient, a-factor processing is abolished. In addition to the
a-factor substrate, RCE1 and Ste24 can both AAX a variety of substrates in the yeast with
both overlapping and differential specificity depending on the nature of the CAAX box
(Trueblood and others 2000). It is still unclear whether or not there are two or more
prelamin A AAXing enzymes present in the mammalian cell. However, the body of
evidence presented in this work argues that Zmpste24 alone mediates the AAXing of
prelamin A. This reasoning comes from the experiments using the Y379Stop Zmpste24
truncation, which was modeled after the mutation found in patients with MAD (Agarwal
and others 2003). Our results indicate that this prematurely truncated form of Zmpste24 is
incompetent for AAXing and fully active for the second endoproteolytic step (Fig 25).
Correlating this in vitro data to the physiological in vivo results suggests that patients
harboring the MAD Zmpste24 mutation would accumulate prelamin A only if another
AAXing enzyme is not present to complement the defect. However, if RCE1 or some
other protease were capable of AAXing prelamin A, then the full complement of post
translational modifications would occur to produce fully mature lamin A because
Zmpste24 would be competent for the second endoproteolytic step. Therefore, if there
were a second complementing AAXing enzyme, this type of Zmpste24 mutation should
result in no phenotype due to normal lamin function. MAD is a disease state with a
pronounced phenotypic effect and, therefore, it follows that Zmpste24 is the only protease
responsible for carrying out AAXing on prelamin A in the human cell. To prove this
assertion, prelamin A should be isolated from MAD patients and mass spectrally
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characterized to identify the exact state of post translational modification present at the
CAAX box. If isolated prelamin A from MAD patients is only partially processed at the
CAAX box by evidence of a prenylated cysteine adjacent to three carboxyl terminal CAAX
box residues, then it can be concluded that Zmpste24 is the only prelamin A specific
AAXing protease within the cell. These data do not argue that all lamins use Zmpste24 as
their sole source of AAXing activity. As an example of this, the processing of Lamin B1,
which has the CAAX box sequence CAIM, is completely abolished in RCE1 -/- mouse cells
but is maintained in Zmpste24 -/- cells (Maske and others 2003). In contrast to the findings
for Lamin B1, we conclude that RCE1 is not involved in the processing of prelamin A. This
may be due to substrate specificity differences and/or lack of accessibility due to
compartmentalization.
This current set of in vitro data suggest that both steps in the maturation of prelamin A
can be catalyzed by Zmpste24. Because the first AAXing reaction is assumed to be solely
governed by Zmpste24 in vivo, this leaves open the possibility that another protease in
addition to Zmpste24 may be able to perform the second endoproteolytic conversion. In
this scenario, the accumulation of unfully processed prelamin A in Zmpste24 -/- cells is not
due to the loss of the second endoproteolytic activity of Zmpste24 because a
complementing protease is able to carry out this processing. Rather, the accumulation of
unprocessed prelamin A stems from the experimental observation that when the first set
of post-translational modifications of AAXing and subsequent carboxymethylation are not
completed at the C-terminus of prelamin A, the second endoproteolytic reaction does not
and can not occur (Kilic and others 1997). This possibility of another protease being found
in the cell that can perform the second endoproteolytic conversion of prelamin A is highly
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unlikely due to the unique specificity and localization requirements for prelamin A
processing, yet this possibility can not be ruled out with the current set of data. In
summary, the possibility that more than one enzyme can perform AAXing on prelamin A is
ruled out by our set of in vitro data along with the MAD phenotype, and the possibility that
a redundant enzyme is present that is capable of the second endoproteolytic reaction can
not be ruled out. Nonetheless, it is entirely possible that Zmpste24 is the sole enzyme
within the cell that performs both steps in prelamin A maturation.
The immunofluorescence data presented in this paper show that Zmpste24
overexpressed in CHO cells has not only an ER localization but a nuclear envelope
localization as well. Previous reports have demonstrated that human Zmpste24 is
localized to the ER and the golgi (Kumagai and others 1999). However, unlike yeast
Ste24, Zmpste24 does not contain a canonical C-terminal ER retention motif (Tam and
others 1998) leading to the possibility that Zmpste24 may be found at other locations
within the cell other than the ER. It is to be noted that because Zmpste24 contains 7
transmembrane domains, it is topologically constrained to membranous structures. The
nuclear localization of Zmpste24 as well as its membrane topology are in agreement with
data from previous work done in our lab that demonstrates purified nuclear envelope
fractions contain endoproteolytic activity (Kilic and others 1997; Kilic and others 1999),
and that the endoproteolytic conversion of prelamin A to lamin A can be accomplished
solely in the nucleus (Lutz and others 1992). One possible processing pathway for
prelamin A that would encompass all of the known data would be a model in which
prelamin A is first synthesized and farnesylated in the cytosol, travels to the ER
membrane to undergo AAXing by Zmpste24 or some other AAXing enzyme, undergoes
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carboxymethylation on the ER by ICMT, and then travels to the nucleus to undergo
endoproteolysis by Zmpste24. For this model to be valid, an explanation describing why
prelamin A does not become converted to lamin A before entering the nucleus would
need to be established because Zmpste24 is clearly present in the ER. One possible
explanation is that another factor or chaperone is interacting with prelamin A and/or
Zmpste24 in such a way as to render endoproteolyis as a nuclear specific event. Another
model with regards to the subcellular localization of prelamin A maturation is one in which
all prelamin A processing occurs solely in the nucleus. Such a model is consistent with
findings that incubating cells in the presence of the prenylation inhibitor lovastatin causes
non prenylated prelamin A to accumulate in the nucleoplasm, after which the
commencement of prenylation causes all prelamin A to lamin A conversion to take place
in the nucleus within 3 hours (Lutz 1992). Full processing of nonprenylated prelamin A to
lamin A solely in the nucleus is made possible by the observation that farnesyltransferase
can be localized to the nucleoplasm (Sinensky and others 1994b). The actual pathway
may be a hybrid between these two models and would open up the possibility that the
extent to which either pathway is being used is a highly regulated process based on tissue
type, differentiation, and state of proliferation.
Previous data from our lab conducted with nuclear envelope extracts demonstrate that
the prelamin A substrate must be prenylated for endoproteolysis to occur, and that
farnesyl cysteine methyl ester acts as a non-competitive inhibitor of endoproteolytic
activity, suggesting that there may be a prenyl-specific binding domain that is separate
and distinct from the active site (Kilic and others 1997). Certainly, the data presented here
for Zmpste24 is in agreement with this prenylation requirement in that: incubating cells
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with lovastatin abolishes the Zmpste24 mediated conversion of prelaminAct to laminAct
(Fig 16); and a prelaminAct substrate bearing a nonprenylated carboxyl-terminal cysteine
is unable to be processed to laminAct by Zmpste24 in vitro (Fig 22). These findings agree
with the prenylation requirement for endoproteolytic conversion but do not address the
specificity or constraints of the prenyl moiety. The prelaminAct substrate constructed in
the insect system possessed a farnesyl cysteine methyl ester (Fig’s 9 and 10) and,
therefore, the results reported here shed light on the specificity of Zmpste24 towards a
farnesyl-moiety as the prenyl substituent. However, in previous studies with crude nuclear
envelope preparations, an artificial substrate mimicking the last 18 residues prelamin A
bearing a farnesyl isoprenoid is 19 times more reactive (Vmax/Km) than the same substrate
containing a geranylgeranyl moiety (Kilic and others 1997). Two hypothesis could explain
this substrate recognition specificity: 1) The “two site hypothesis” in which a prenyl
binding site directly resides on Zmpste24 along with the active site, and 2) The “other
factor hypothesis” in which some other prenyl-specific recognition cofactor or membrane
anchor is involved in properly presenting the substrate to the active site of Zmpste24. The
most likely candidate for a prenylation dependent anchoring protein is NARF, a nuclear
membrane associated protein that binds the C-terminal tail of prelamin A with prenylation
dependent specificity (Barton and Worman 1999). It would be interesting to explore the
phenotype of NARF-/- mice to determine if they exhibit similar phenotypes to known
laminopathies. Additionally, it would be informative to analyze the fate of prelamin A in
cells derived from these mice by examining the extent of processing. Finding both a
laminopathy like phenotype and defective processing or prelamin A would demonstrate
whether or not the interaction between farnesylated prelamin A and NARF is necessary
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for downstream prelamin A processing events (i.e., AAXing, carboxymethylation, and
endoproteolysis).
These similarities between the yeast and human forms of the enzyme are limited in
extent as the results of this present study reveal that the mechanistic features of these
two enzymes diverge significantly. Performing an inhibition profile on Zmpste24 revealed
that the endoproteolytic activity is solely chymotrypsin like (Fig 23), while the AAXing
reaction is distinctly Zn+2 dependent (Fig 15). This latter result was as expected because
the AAXing activity of human Zmpste24 against the yeast substrate a-factor has been
firmly established as a Zn+2 dependent process (Tam and others 1998; Schmidt and
others 2000). As a confirmation to the data observed in the inhibition response profiles, a
mutant of Zmpste24 containing a deletion of the HEXXH motif was incompetent for
AAXing, but faithfully maintained endoproteolytic activity (Fig 25).The unexpected
observation that endoproteolysis is mediated by a serine like functionality naturally led to
the hypothesis that a second, yet distinct, active site existed within the same enzyme.
Since we were not able to reconstitute the second endoproteolytic activity from detergent
extracted and purified Zmpste24 with any success, we could not rule out the possibility
that Zmpste24 was functioning as a cofactor, membrane anchor, or shuttling effector to
present the substrate to the bona fide prelamin A endoprotease. With this possibility in
mind, we attempted to affinity label Zmpste24 with FFCK, a fluorescently derived
analogue to the chymotrypsin specific suicide inhibitor TPCK. Inhibition by this family of
chloromethyl ketones function by specifically and covalently alkylating the active site
histidine within the catalytic triad, thereby rendering it non-functional (Grabarek and
others 2002b). Our results indicated that Zmpste24 can be efficiently labeled with FFCK
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and that such labeling is abolished if the enzyme is first incubated in the presence of
TPCK. Mass spectral analysis of the purified FFCK labeled band mass fingerprinted this
as Zmpste24, although a definitively FFCK labeled peptide was not able to be identified in
the spectra. However, the observation that the chymotrypsin affinity label FFCK was able
to directly tag the Zmpste24 enzyme supported the hypothesis that the serine like active
site resides directly within Zmpste24. This is in agreement with previous experiments on
purified nuclear envelope fractions that demonstrated the endoproteolytic activity is
mediated by a chymotrypsin like enzyme (Kilic and others 1999). These data taken
together with the fact that the endoproteolytic reaction is inhibited by TPCK and FFCK,
provides strong evidence that there is a chymotrypsin like active site within Zmpste24.
Further evaluation of this “two active site” hypothesis should be conducted in the future
using site directed mutagenesis of the putative serine and/or histidine residues, and then
assaying for endoproteolytic activity. Other labeling compounds to aid in the identification
of the putative serine residue include diisopropylfluorophosphonate (DFP), and
aminoethylbenzenesulfonlyfluoride (AEBSF), specific compounds that covalenlty attach
to the serine catalytic residue of serine-like enzymes. Radiolabeled forms of these
compounds can be used to follow HPLC separated peptides from a tryptic digest of
labeled Zmpste24. Positive fractions can be pooled and subjected to MS/MS or Edman
degradation to identify the corresponding residues. Future studies encompassing the new
questions raised by this current research will provide a more in depth knowledge of the
nature and function of these two active sites.

110

REFERENCES

Aebi U, Cohn J, Buhle L, Gerace L. 1986. The nuclear lamina is a meshwork of
intermediate-type filaments. Nature 323(6088):560-4.
Agarwal AK, Fryns JP, Auchus RJ, Garg A. 2003. Zinc metalloproteinase, ZMPSTE24, is
mutated in mandibuloacral dysplasia. Hum Mol Genet 12(16):1995-2001.
Anderegg RJ, Betz R, Carr SA, Crabb JW, Duntze W. 1988. Structure of Saccharomyces
cerevisiae mating hormone a-factor. Identification of S-farnesyl cysteine as a
structural component. J Biol Chem 263(34):18236-40.
Armstrong SA, Hannah VC, Goldstein JL, Brown MS. 1995. CAAX geranylgeranyl
transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB. J Biol
Chem 270(14):7864-8.
Barrett AJ, Rawlings ND. 1995. Families and clans of serine peptidases. Arch Biochem
Biophys 318(2):247-50.
Barton RM, Worman HJ. 1999. Prenylated prelamin A interacts with Narf, a novel nuclear
protein. J Biol Chem 274(42):30008-18.
Beck LA, Hosick TJ, Sinensky M. 1990. Isoprenylation is required for the processing of
the lamin A precursor. J Cell Biol 110(5):1489-99.
Bergo MO, Gavino B, Ross J, Schmidt WK, Hong C, Kendall LV, Mohr A, Meta M, Genant
H, Jiang Y and others. 2002. Zmpste24 deficiency in mice causes spontaneous
bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl
Acad Sci U S A 99(20):13049-54.
Biamonti G, Giacca M, Perini G, Contreas G, Zentilin L, Weighardt F, Guerra M, Della
Valle G, Saccone S, Riva S and others. 1992. The gene for a novel human lamin
maps at a highly transcribed locus of chromosome 19 which replicates at the onset
of S-phase. Mol Cell Biol 12(8):3499-506.
Black SD. 1992. Development of hydrophobicity parameters for prenylated proteins.
Biochem Biophys Res Commun 186(3):1437-42.
111

Bonne G, Di Barletta MR, Varnous S, Becane HM, Hammouda EH, Merlini L, Muntoni F,
Greenberg CR, Gary F, Urtizberea JA and others. 1999. Mutations in the gene
encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular
dystrophy. Nat Genet 21(3):285-8.
Boyartchuk VL, Ashby MN, Rine J. 1997. Modulation of Ras and a-factor function by
carboxyl-terminal proteolysis. Science 275(5307):1796-800.
Boyartchuk VL, Rine J. 1998. Roles of prenyl protein proteases in maturation of
Saccharomyces cerevisiae a-factor. Genetics 150(1):95-101.
Broers JL, Machiels BM, Kuijpers HJ, Smedts F, van den Kieboom R, Raymond Y,
Ramaekers FC. 1997. A- and B-type lamins are differentially expressed in normal
human tissues. Histochem Cell Biol 107(6):505-17.
Burke B, Stewart CL. 2002. Life at the edge: the nuclear envelope and human disease.
Nat Rev Mol Cell Biol 3(8):575-85.
Capanni C, Mattioli E, Columbaro M, Lucarelli E, Parnaik VK, Novelli G, Wehnert M,
Cenni V, Maraldi NM, Squarzoni S and others. 2005. Altered pre-lamin A
processing is a common mechanism leading to lipodystrophy. Hum Mol Genet
14(11):1489-502.
Chen L, Lee L, Kudlow BA, Dos Santos HG, Sletvold O, Shafeghati Y, Botha EG, Garg A,
Hanson NB, Martin GM and others. 2003. LMNA mutations in atypical Werner's
syndrome. Lancet 362(9382):440-5.
Chen P, Sapperstein SK, Choi JD, Michaelis S. 1997. Biogenesis of the Saccharomyces
cerevisiae mating pheromone a-factor. J Cell Biol 136(2):251-69.
Coulombe PA, Ma L, Yamada S, Wawersik M. 2001. Intermediate filaments at a glance. J
Cell Sci 114(Pt 24):4345-7.
Dagenais A, Bibor-Hardy V, Laliberte JF, Royal A, Simard R. 1985. Detection in BHK cells
of a precursor form for lamin A. Exp Cell Res 161(2):269-76.
De Sandre-Giovannoli A, Chaouch M, Kozlov S, Vallat JM, Tazir M, Kassouri N,
Szepetowski P, Hammadouche T, Vandenberghe A, Stewart CL and others. 2002.
Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins,

112

cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth
disorder type 2) and mouse. Am J Hum Genet 70(3):726-36.
Dessev GN. 1992. Nuclear envelope structure. Curr Opin Cell Biol 4(3):430-5.
Dreuillet C, Tillit J, Kress M, Ernoult-Lange M. 2002. In vivo and in vitro interaction
between human transcription factor MOK2 and nuclear lamin A/C. Nucleic Acids
Res 30(21):4634-42.
Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins
CM, Moses TY, Berglund P and others. 2003. Recurrent de novo point mutations
in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423(6937):293-8.
Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, Atherton J, Vidaillet HJ,
Jr., Spudich S, De Girolami U and others. 1999. Missense mutations in the rod
domain of the lamin A/C gene as causes of dilated cardiomyopathy and
conduction-system disease. N Engl J Med 341(23):1715-24.
Fawcett DW. 1966. On the occurrence of a fibrous lamina on the inner aspect of the
nuclear envelope in certain cells of vertebrates. Am J Anat 119(1):129-45.
Fisher DZ, Chaudhary N, Blobel G. 1986. cDNA sequencing of nuclear lamins A and C
reveals primary and secondary structural homology to intermediate filament
proteins. Proc Natl Acad Sci U S A 83(17):6450-4.
Fong LG, Ng JK, Meta M, Cote N, Yang SH, Stewart CL, Sullivan T, Burghardt A,
Majumdar S, Reue K and others. 2004. Heterozygosity for Lmna deficiency
eliminates the progeria-like phenotypes in Zmpste24-deficient mice. Proc Natl
Acad Sci U S A 101(52):18111-6.
Fu HW, Casey PJ. 1999. Enzymology and biology of CaaX protein prenylation. Recent
Prog Horm Res 54:315-42; discussion 342-3.
Fujimura-Kamada K, Nouvet FJ, Michaelis S. 1997. A novel membrane-associated
metalloprotease, Ste24p, is required for the first step of NH2-terminal processing
of the yeast a-factor precursor. J Cell Biol 136(2):271-85.
Furukawa K, Hotta Y. 1993. cDNA cloning of a germ cell specific lamin B3 from mouse
spermatocytes and analysis of its function by ectopic expression in somatic cells.
Embo J 12(1):97-106.
113

Furukawa K, Inagaki H, Hotta Y. 1994. Identification and cloning of an mRNA coding for a
germ cell-specific A-type lamin in mice. Exp Cell Res 212(2):426-30.
Gerace L, Blobel G. 1980. The nuclear envelope lamina is reversibly depolymerized
during mitosis. Cell 19(1):277-87.
Gerace L, Burke B. 1988. Functional organization of the nuclear envelope. Annu Rev Cell
Biol 4:335-74.
Gerace L, Comeau C, Benson M. 1984. Organization and modulation of nuclear lamina
structure. J Cell Sci Suppl 1:137-60.
Glomset JA, Gelb MH, Farnsworth CC. 1990. Prenyl proteins in eukaryotic cells: a new
type of membrane anchor. Trends Biochem Sci 15(4):139-42.
Goldman RD, Goldman AE, Shumaker DK. 2005. Nuclear lamins: building blocks of
nuclear structure and function. Novartis Found Symp 264:3-16; discussion 16-21,
227-30.
Goldman RD, Gruenbaum Y, Moir RD, Shumaker DK, Spann TP. 2002. Nuclear lamins:
building blocks of nuclear architecture. Genes Dev 16(5):533-47.
Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon LB,
Gruenbaum Y, Khuon S, Mendez M, Varga R and others. 2004. Accumulation of
mutant lamin A causes progressive changes in nuclear architecture in
Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 101(24):8963-8.
Goldstein JL, Brown MS, Stradley SJ, Reiss Y, Gierasch LM. 1991. Nonfarnesylated
tetrapeptide inhibitors of protein farnesyltransferase. J Biol Chem
266(24):15575-8.
Gotzmann J, Foisner R. 1999. Lamins and lamin-binding proteins in functional chromatin
organization. Crit Rev Eukaryot Gene Expr 9(3-4):257-65.
Grabarek J, Ardelt B, Du L, Darzynkiewicz Z. 2002a. Activation of caspases and serine
proteases during apoptosis induced by onconase (Ranpirnase). Exp Cell Res
278(1):61-71.
Grabarek J, Dragan M, Lee BW, Johnson GL, Darzynkiewicz Z. 2002b. Activation of
chymotrypsin-like serine protease(s) during apoptosis detected by affinity-labeling
of the enzymatic center with fluoresceinated inhibitor. Int J Oncol 20(2):225-33.
114

Gruber J, Lampe T, Osborn M, Weber K. 2005. RNAi of FACE1 protease results in growth
inhibition of human cells expressing lamin A: implications for Hutchinson-Gilford
progeria syndrome. J Cell Sci.
Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K. 2001. Identification of essential
genes in cultured mammalian cells using small interfering RNAs. J Cell Sci 114(Pt
24):4557-65.
Hennekes H, Nigg EA. 1994. The role of isoprenylation in membrane attachment of
nuclear lamins. A single point mutation prevents proteolytic cleavage of the lamin
A precursor and confers membrane binding properties. J Cell Sci 107 (Pt
4):1019-29.
Holtz D, Tanaka RA, Hartwig J, McKeon F. 1989. The CaaX motif of lamin A functions in
conjunction with the nuclear localization signal to target assembly to the nuclear
envelope. Cell 59(6):969-77.
Hooper NM. 1994. Families of zinc metalloproteases. FEBS Lett 354(1):1-6.
Hrycyna CA, Wait SJ, Backlund PS, Jr., Michaelis S. 1995. Yeast STE14
methyltransferase, expressed as TrpE-STE14 fusion protein in Escherichia coli,
for in vitro carboxylmethylation of prenylated polypeptides. Methods Enzymol
250:251-66.
Hutchison CJ, Alvarez-Reyes M, Vaughan OA. 2001. Lamins in disease: why do
ubiquitously expressed nuclear envelope proteins give rise to tissue-specific
disease phenotypes? J Cell Sci 114(Pt 1):9-19.
Hutchison CJ, Worman HJ. 2004. A-type lamins: guardians of the soma? Nat Cell Biol
6(11):1062-7.
Khosravi-Far R, Der CJ. 1995. Prenylation analysis of bacterially expressed and insect
cell-expressed Ras and Ras-related proteins. Methods Enzymol 255:46-60.
Kilic F, Dalton MB, Burrell SK, Mayer JP, Patterson SD, Sinensky M. 1997. In vitro assay
and characterization of the farnesylation-dependent prelamin A endoprotease. J
Biol Chem 272(8):5298-304.

115

Kilic F, Johnson DA, Sinensky M. 1999. Subcellular localization and partial purification of
prelamin A endoprotease: an enzyme which catalyzes the conversion of
farnesylated prelamin A to mature lamin A. FEBS Lett 450(1-2):61-5.
Kim JB, Spiegelman BM. 1996. ADD1/SREBP1 promotes adipocyte differentiation and
gene expression linked to fatty acid metabolism. Genes Dev 10(9):1096-107.
Kisselev O, Ermolaeva M, Gautam N. 1995. Efficient interaction with a receptor requires a
specific type of prenyl group on the G protein gamma subunit. J Biol Chem
270(43):25356-8.
Kourmouli N, Theodoropoulos PA, Dialynas G, Bakou A, Politou AS, Cowell IG, Singh
PB, Georgatos SD. 2000. Dynamic associations of heterochromatin protein 1 with
the nuclear envelope. Embo J 19(23):6558-68.
Krohne G, Benavente R. 1986. The nuclear lamins. A multigene family of proteins in
evolution and differentiation. Exp Cell Res 162(1):1-10.
Kumagai H, Kawamura Y, Yanagisawa K, Komano H. 1999. Identification of a human
cDNA encoding a novel protein structurally related to the yeast
membrane-associated metalloprotease, Ste24p. Biochim Biophys Acta
1426(3):468-74.
Kumaran RI, Muralikrishna B, Parnaik VK. 2002. Lamin A/C speckles mediate spatial
organization of splicing factor compartments and RNA polymerase II transcription.
J Cell Biol 159(5):783-93.
Lamond AI, Earnshaw WC. 1998. Structure and function in the nucleus. Science
280(5363):547-53.
Lehner CF, Furstenberger G, Eppenberger HM, Nigg EA. 1986. Biogenesis of the nuclear
lamina: in vivo synthesis and processing of nuclear protein precursors. Proc Natl
Acad Sci U S A 83(7):2096-9.
Leonard WJ, Imada K, Nakajima H, Puel A, Soldaini E, John S. 1999. Signaling via the
IL-2 and IL-7 receptors from the membrane to the nucleus. Cold Spring Harb Symp
Quant Biol 64:417-24.

116

Leung GK, Schmidt WK, Bergo MO, Gavino B, Wong DH, Tam A, Ashby MN, Michaelis S,
Young SG. 2001. Biochemical studies of Zmpste24-deficient mice. J Biol Chem
276(31):29051-8.
Lloyd DJ, Trembath RC, Shackleton S. 2002. A novel interaction between lamin A and
SREBP1: implications for partial lipodystrophy and other laminopathies. Hum Mol
Genet 11(7):769-77.
Luderus ME, den Blaauwen JL, de Smit OJ, Compton DA, van Driel R. 1994. Binding of
matrix attachment regions to lamin polymers involves single-stranded regions and
the minor groove. Mol Cell Biol 14(9):6297-305.
Lutz RJ, Trujillo MA, Denham KS, Wenger L, Sinensky M. 1992. Nucleoplasmic
localization of prelamin A: implications for prenylation-dependent lamin A
assembly into the nuclear lamina. Proc Natl Acad Sci U S A 89(7):3000-4.
Macara IG. 2001. Transport into and out of the nucleus. Microbiol Mol Biol Rev
65(4):570-94, table of contents.
Mancini MA, Shan B, Nickerson JA, Penman S, Lee WH. 1994. The retinoblastoma gene
product is a cell cycle-dependent, nuclear matrix-associated protein. Proc Natl
Acad Sci U S A 91(1):418-22.
Marshall CJ. 1993. Protein prenylation: a mediator of protein-protein interactions. Science
259(5103):1865-6.
Marshall WF, Dernburg AF, Harmon B, Agard DA, Sedat JW. 1996. Specific interactions
of chromatin with the nuclear envelope: positional determination within the nucleus
in Drosophila melanogaster. Mol Biol Cell 7(5):825-42.
Maske CP, Hollinshead MS, Higbee NC, Bergo MO, Young SG, Vaux DJ. 2003. A
carboxyl-terminal interaction of lamin B1 is dependent on the CAAX endoprotease
Rce1 and carboxymethylation. J Cell Biol 162(7):1223-32.
McKeon FD, Kirschner MW, Caput D. 1986. Homologies in both primary and secondary
structure between nuclear envelope and intermediate filament proteins. Nature
319(6053):463-8.
Mizuno S. 1999. [Review: functional structure and protein molecular complexes in the cell
nucleus]. Tanpakushitsu Kakusan Koso 44(12 Suppl):1645-64.
117

Moores SL, Schaber MD, Mosser SD, Rands E, O'Hara MB, Garsky VM, Marshall MS,
Pompliano DL, Gibbs JB. 1991. Sequence dependence of protein isoprenylation. J
Biol Chem 266(22):14603-10.
Mounkes L, Kozlov S, Burke B, Stewart CL. 2003. The laminopathies: nuclear structure
meets disease. Curr Opin Genet Dev 13(3):223-30.
Muchir A, Bonne G, van der Kooi AJ, van Meegen M, Baas F, Bolhuis PA, de Visser M,
Schwartz K. 2000. Identification of mutations in the gene encoding lamins A/C in
autosomal dominant limb girdle muscular dystrophy with atrioventricular
conduction disturbances (LGMD1B). Hum Mol Genet 9(9):1453-9.
Muchir A, van Engelen BG, Lammens M, Mislow JM, McNally E, Schwartz K, Bonne G.
2003. Nuclear envelope alterations in fibroblasts from LGMD1B patients carrying
nonsense Y259X heterozygous or homozygous mutation in lamin A/C gene. Exp
Cell Res 291(2):352-62.
Navarro CL, Cadinanos J, Sandre-Giovannoli AD, Bernard R, Courrier S, Boccaccio I,
Boyer A, Kleijer WJ, Wagner A, Giuliano F and others. 2005. Loss of ZMPSTE24
(FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of
Lamin A precursors. Hum Mol Genet 14(11):1503-13.
Navarro CL, De Sandre-Giovannoli A, Bernard R, Boccaccio I, Boyer A, Genevieve D,
Hadj-Rabia S, Gaudy-Marqueste C, Smitt HS, Vabres P and others. 2004. Lamin A
and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify
restrictive dermopathy as a lethal neonatal laminopathy. Hum Mol Genet
13(20):2493-503.
Novelli G, Muchir A, Sangiuolo F, Helbling-Leclerc A, D'Apice MR, Massart C, Capon F,
Sbraccia P, Federici M, Lauro R and others. 2002. Mandibuloacral dysplasia is
caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet
71(2):426-31.
Ognibene A, Sabatelli P, Petrini S, Squarzoni S, Riccio M, Santi S, Villanova M, Palmeri
S, Merlini L, Maraldi NM. 1999. Nuclear changes in a case of X-linked
Emery-Dreifuss muscular dystrophy. Muscle Nerve 22(7):864-9.

118

Ong EB, Shaw E, Schoellmann G. 1965. The Identification Of The Histidine Residue At
The Active Center Of Chymotrypsin. J Biol Chem 240:694-8.
Ostlund C, Bonne G, Schwartz K, Worman HJ. 2001. Properties of lamin A mutants found
in Emery-Dreifuss muscular dystrophy, cardiomyopathy and Dunnigan-type partial
lipodystrophy. J Cell Sci 114(Pt 24):4435-45.
Ostlund C, Worman HJ. 2003. Nuclear envelope proteins and neuromuscular diseases.
Muscle Nerve 27(4):393-406.
Otto JC, Kim E, Young SG, Casey PJ. 1999. Cloning and characterization of a
mammalian prenyl protein-specific protease. J Biol Chem 274(13):8379-82.
Paddy MR, Belmont AS, Saumweber H, Agard DA, Sedat JW. 1990. Interphase nuclear
envelope lamins form a discontinuous network that interacts with only a fraction of
the chromatin in the nuclear periphery. Cell 62(1):89-106.
Pendas AM, Zhou Z, Cadinanos J, Freije JM, Wang J, Hultenby K, Astudillo A, Wernerson
A, Rodriguez F, Tryggvason K and others. 2002. Defective prelamin A processing
and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient
mice. Nat Genet 31(1):94-9.
Pfaller R, Newport JW. 1995. Assembly/disassembly of the nuclear envelope membrane.
Characterization of the membrane-chromatin interaction using partially purified
regulatory enzymes. J Biol Chem 270(32):19066-72.
Pollard KM, Chan EK, Grant BJ, Sullivan KF, Tan EM, Glass CA. 1990. In vitro
posttranslational modification of lamin B cloned from a human T-cell line. Mol Cell
Biol 10(5):2164-75.
Raharjo WH, Enarson P, Sullivan T, Stewart CL, Burke B. 2001. Nuclear envelope
defects associated with LMNA mutations cause dilated cardiomyopathy and
Emery-Dreifuss muscular dystrophy. J Cell Sci 114(Pt 24):4447-57.
Rando RR. 1996. Chemical biology of protein isoprenylation/methylation. Biochim
Biophys Acta 1300(1):5-16.
Rao L, Perez D, White E. 1996. Lamin proteolysis facilitates nuclear events during
apoptosis. J Cell Biol 135(6 Pt 1):1441-55.

119

Rawlings ND, Barrett AJ. 1994. Families of serine peptidases. Methods Enzymol
244:19-61.
Rober RA, Sauter H, Weber K, Osborn M. 1990. Cells of the cellular immune and
hemopoietic system of the mouse lack lamins A/C: distinction versus other somatic
cells. J Cell Sci 95 (Pt 4):587-98.
Rober RA, Weber K, Osborn M. 1989. Differential timing of nuclear lamin A/C expression
in the various organs of the mouse embryo and the young animal: a developmental
study. Development 105(2):365-78.
Roberts AB. 1999. TGF-beta signaling from receptors to the nucleus. Microbes Infect
1(15):1265-73.
Schmidt WK, Tam A, Michaelis S. 2000. Reconstitution of the Ste24p-dependent
N-terminal proteolytic step in yeast a-factor biogenesis. J Biol Chem
275(9):6227-33.
Schrander-Stumpel C, Spaepen A, Fryns JP, Dumon J. 1992. A severe case of
mandibuloacral dysplasia in a girl. Am J Med Genet 43(5):877-81.
Seabra MC, Goldstein JL, Sudhof TC, Brown MS. 1992. Rab geranylgeranyl transferase.
A multisubunit enzyme that prenylates GTP-binding proteins terminating in
Cys-X-Cys or Cys-Cys. J Biol Chem 267(20):14497-503.
Shackleton S, Lloyd DJ, Jackson SN, Evans R, Niermeijer MF, Singh BM, Schmidt H,
Brabant G, Kumar S, Durrington PN and others. 2000. LMNA, encoding lamin A/C,
is mutated in partial lipodystrophy. Nat Genet 24(2):153-6.
Shackleton S, Smallwood DT, Clayton P, Wilson LC, Agarwal AK, Garg A, Trembath RC.
2005. Compound heterozygous ZMPSTE24 mutations reduce prelamin A
processing and result in a severe progeroid phenotype. J Med Genet 42(6):e36.
Shaw E, Ruscica J. 1971. The reactivity of His-57 in chymotrypsin to alkylation. Arch
Biochem Biophys 145(2):484-9.
Sinensky M, Beck LA, Leonard S, Evans R. 1990. Differential inhibitory effects of
lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem
265(32):19937-41.

120

Sinensky M, Fantle K, Dalton M. 1994a. An antibody which specifically recognizes
prelamin A but not mature lamin A: application to detection of blocks in
farnesylation-dependent protein processing. Cancer Res 54(12):3229-32.
Sinensky M, Fantle K, Trujillo M, McLain T, Kupfer A, Dalton M. 1994b. The processing
pathway of prelamin A. J Cell Sci 107 (Pt 1):61-7.
Spann TP, Moir RD, Goldman AE, Stick R, Goldman RD. 1997. Disruption of nuclear
lamin organization alters the distribution of replication factors and inhibits DNA
synthesis. J Cell Biol 136(6):1201-12.
Steen RL, Collas P. 2001. Mistargeting of B-type lamins at the end of mitosis: implications
on cell survival and regulation of lamins A/C expression. J Cell Biol 153(3):621-6.
Stewart C, Burke B. 1987. Teratocarcinoma stem cells and early mouse embryos contain
only a single major lamin polypeptide closely resembling lamin B. Cell
51(3):383-92.
Stuurman N, Heins S, Aebi U. 1998. Nuclear lamins: their structure, assembly, and
interactions. J Struct Biol 122(1-2):42-66.
Sullivan T, Escalante-Alcalde D, Bhatt H, Anver M, Bhat N, Nagashima K, Stewart CL,
Burke B. 1999. Loss of A-type lamin expression compromises nuclear envelope
integrity leading to muscular dystrophy. J Cell Biol 147(5):913-20.
Tam A, Nouvet FJ, Fujimura-Kamada K, Slunt H, Sisodia SS, Michaelis S. 1998. Dual
roles for Ste24p in yeast a-factor maturation: NH2-terminal proteolysis and
COOH-terminal CAAX processing. J Cell Biol 142(3):635-49.
Tam A, Schmidt WK, Michaelis S. 2001. The multispanning membrane protein Ste24p
catalyzes CAAX proteolysis and NH2-terminal processing of the yeast a-factor
precursor. J Biol Chem 276(50):46798-806.
Taniura H, Glass C, Gerace L. 1995. A chromatin binding site in the tail domain of nuclear
lamins that interacts with core histones. J Cell Biol 131(1):33-44.
Trueblood CE, Boyartchuk VL, Picologlou EA, Rozema D, Poulter CD, Rine J. 2000. The
CaaX proteases, Afc1p and Rce1p, have overlapping but distinct substrate
specificities. Mol Cell Biol 20(12):4381-92.

121

Ulitzur N, Harel A, Feinstein N, Gruenbaum Y. 1992. Lamin activity is essential for nuclear
envelope assembly in a Drosophila embryo cell-free extract. J Cell Biol
119(1):17-25.
Vorburger K, Kitten GT, Nigg EA. 1989. Modification of nuclear lamin proteins by a
mevalonic acid derivative occurs in reticulocyte lysates and requires the cysteine
residue of the C-terminal CXXM motif. Embo J 8(13):4007-13.
Weber K, Plessmann U, Traub P. 1989. Maturation of nuclear lamin A involves a specific
carboxy-terminal trimming, which removes the polyisoprenylation site from the
precursor; implications for the structure of the nuclear lamina. FEBS Lett
257(2):411-4.
Worman HJ, Courvalin JC. 2000. The inner nuclear membrane. J Membr Biol
177(1):1-11.
Ye Q, Worman HJ. 1994. Primary structure analysis and lamin B and DNA binding of
human LBR, an integral protein of the nuclear envelope inner membrane. J Biol
Chem 269(15):11306-11.
Zhang FL, Casey PJ. 1996. Protein prenylation: molecular mechanisms and functional
consequences. Annu Rev Biochem 65:241-69.
Zhivotovsky B, Gahm A, Orrenius S. 1997. Two different proteases are involved in the
proteolysis of lamin during apoptosis. Biochem Biophys Res Commun
233(1):96-101.

122

VITA
Douglas P. Corrigan
Personal Data:

Education:

Professional
Experience:

Publications:

Honors and
Awards:

Date of Birth: January 16, 1972
Place of Birth: Rahway, New Jersey
Marital Status: Married
Rensselaer Polytechnic Institute, Troy, New York;
Engineering Physics, B.S., 1995
Rensselaer Polytechnic Institute, Troy, New York;
Engineering Physics, M.S., 1997
East Tennessee State University, Johnson City, Tennessee;
Biochemistry and Molecular Biology, Ph.D., 2005

Physics Researcher, Department of Physics, Oak Ridge National
Laboratory; Oak Ridge, Tennessee, 1991-1997
NASA Research Graduate Fellow, Marshall Space Flight Center;
Huntsville, Alabama 1994-1997
Graduate Assistant, East Tennessee State University, College of
Medicine, 2000 – 2005
Corrigan DP, Kuszczak D, Rusinol AE, Thewke DP, Hrycyna CA,
Michaelis S, Sinensky MS. Prelamin A endoproteolytic processing
in vitro by recombinant Zmpste24. Biochem J. 2004 Oct 13
Corrigan, D.P.; Koss, M. B.; LaCombe, J. C.; de Jager, K. D.;
Tennenhouse, L. A.; Glicksman, M. E.; “Experimental
measurements of sidebranching in thermal dendrites under
terrestrial-gravity and microgravity conditions”, Phys. Rev. E., Vol.
60, No.6, pp. 7217-7223, (1999)
J.C. LaCombe, M.B.Koss, D.P. Corrigan, A.O. Lupulescu and L.A.
Tennenhouse "Implications of the interface shape on steady-state
dendritic crystal growth", J. Crystal Growth, Vol 206, No. 4, pp.
225-352, (1999)

Enrico Fermi Award, 1990
Walter C. Sharp Scholarship, 1990-1994
Phillip Gaertner Award, 1994
123

